{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T19:10:03.342443+00:00","company":{"ticker":"IVF","cik":1417926,"company_name":"INVO Fertility, Inc."},"pagination":{"limit":100,"returned":100,"next_cursor":"2023-04-17T23:59:59+00:00|165488"},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"WFRSA and The Elizabeth Pritts Revocable Living Trust","detail":"asset_purchase","count":4,"first_seen":"2023-03-20T23:59:59+00:00","last_seen":"2023-06-30T23:59:59+00:00","evidence_fact_ids":[134118,136681,170811,170813]},{"display_name":"Maxim Group LLC","detail":"underwriting","count":3,"first_seen":"2023-03-28T23:59:59+00:00","last_seen":"2025-12-05T23:59:59+00:00","evidence_fact_ids":[121946,140842,168808]},{"display_name":"NAYA Biosciences, Inc.","detail":"merger","count":3,"first_seen":"2023-10-26T23:59:59+00:00","last_seen":"2024-01-10T23:59:59+00:00","evidence_fact_ids":[81915,81916,103324]},{"display_name":"Armistice Capital Markets Ltd.","detail":"equity_purchase","count":2,"first_seen":"2023-07-07T23:59:59+00:00","last_seen":"2023-07-07T23:59:59+00:00","evidence_fact_ids":[133056,133057]},{"display_name":"FLOW, IVF Science, LLC, and Dr. Elizabeth Pritts as trustee for the Elizabeth Pritts Revocable List Trust","detail":"equity_purchase","count":2,"first_seen":"2023-03-20T23:59:59+00:00","last_seen":"2023-06-30T23:59:59+00:00","evidence_fact_ids":[134119,170812]},{"display_name":"FirstFire Global Opportunities Fund, LLC","detail":"equity_purchase","count":2,"first_seen":"2023-02-23T23:59:59+00:00","last_seen":"2024-04-11T23:59:59+00:00","evidence_fact_ids":[62138,177099]},{"display_name":"Transfer Online, Inc.","detail":"other","count":2,"first_seen":"2023-08-08T23:59:59+00:00","last_seen":"2024-04-17T23:59:59+00:00","evidence_fact_ids":[61388,121947]},{"display_name":"Triton Funds LP","detail":"equity_purchase","count":2,"first_seen":"2024-04-01T23:59:59+00:00","last_seen":"2024-04-02T23:59:59+00:00","evidence_fact_ids":[63520,63791]},{"display_name":"Brown Fertility Associates PA","detail":"lease","count":1,"first_seen":"2024-04-19T23:59:59+00:00","last_seen":"2024-04-19T23:59:59+00:00","evidence_fact_ids":[60476]},{"display_name":"Cedar Advance LLC","detail":"credit_facility","count":1,"first_seen":"2023-07-21T23:59:59+00:00","last_seen":"2023-07-21T23:59:59+00:00","evidence_fact_ids":[129410]},{"display_name":"Cytovia Therapeutics Holdings, Inc.","detail":"equity_purchase","count":1,"first_seen":"2023-11-20T23:59:59+00:00","last_seen":"2023-11-20T23:59:59+00:00","evidence_fact_ids":[92071]},{"display_name":"Decathlon Alpha V LP","detail":"credit_facility","count":1,"first_seen":"2023-10-05T23:59:59+00:00","last_seen":"2023-10-05T23:59:59+00:00","evidence_fact_ids":[108298]},{"display_name":"FLOW Sellers","detail":"equity_purchase","count":1,"first_seen":"2023-07-13T23:59:59+00:00","last_seen":"2023-07-13T23:59:59+00:00","evidence_fact_ids":[131837]},{"display_name":"FLOW, IVF Science, LLC, and certain selling members","detail":"asset_purchase","count":1,"first_seen":"2023-06-21T23:59:59+00:00","last_seen":"2023-06-21T23:59:59+00:00","evidence_fact_ids":[136682]},{"display_name":"FLOW, IVF Science, LLC, owned by Wael Megid, Ph.D., and Dr. Elizabeth Pritts as trustee for the Elizabeth Pritts Revocable List Trust","detail":"equity_purchase","count":1,"first_seen":"2023-03-20T23:59:59+00:00","last_seen":"2023-03-20T23:59:59+00:00","evidence_fact_ids":[170814]},{"display_name":"Family Beginnings, P.C. and James Donahue MD","detail":"asset_purchase","count":1,"first_seen":"2025-12-17T23:59:59+00:00","last_seen":"2025-12-17T23:59:59+00:00","evidence_fact_ids":[118952]},{"display_name":"Fertility Labs of Wisconsin, LLC","detail":"asset_purchase","count":1,"first_seen":"2023-08-02T23:59:59+00:00","last_seen":"2023-08-02T23:59:59+00:00","evidence_fact_ids":[125066]},{"display_name":"JAG Multi Investments LLC","detail":"other","count":1,"first_seen":"2023-07-21T23:59:59+00:00","last_seen":"2023-07-21T23:59:59+00:00","evidence_fact_ids":[129411]},{"display_name":"Ming Mei Technology Co. Ltd","detail":"supply","count":1,"first_seen":"2023-01-05T23:59:59+00:00","last_seen":"2023-01-05T23:59:59+00:00","evidence_fact_ids":[187620]},{"display_name":"NAYA","detail":"equity_purchase","count":1,"first_seen":"2024-01-10T23:59:59+00:00","last_seen":"2024-01-10T23:59:59+00:00","evidence_fact_ids":[81917]},{"display_name":"Peak One Opportunity Fund, LP","detail":"equity_purchase","count":1,"first_seen":"2023-02-09T23:59:59+00:00","last_seen":"2023-02-09T23:59:59+00:00","evidence_fact_ids":[180432]},{"display_name":"Required Holders","detail":"notes_offering","count":1,"first_seen":"2024-01-10T23:59:59+00:00","last_seen":"2024-01-10T23:59:59+00:00","evidence_fact_ids":[81918]},{"display_name":"Required Holders of Convertible Notes","detail":"notes_offering","count":1,"first_seen":"2024-01-03T23:59:59+00:00","last_seen":"2024-01-03T23:59:59+00:00","evidence_fact_ids":[84004]},{"display_name":"Wisconsin Fertility and Reproductive Surgery Associates, S.C.","detail":"asset_purchase","count":1,"first_seen":"2023-08-02T23:59:59+00:00","last_seen":"2023-08-02T23:59:59+00:00","evidence_fact_ids":[125065]},{"display_name":"Wisconsin Fertility and Reproductive Surgery Associates, S.C., The Elizabeth Pritts Revocable Living Trust, and Dr. Elizabeth Pritts","detail":"asset_purchase","count":1,"first_seen":"2023-07-13T23:59:59+00:00","last_seen":"2023-07-13T23:59:59+00:00","evidence_fact_ids":[131836]},{"display_name":"a merchant","detail":"other","count":1,"first_seen":"2023-09-01T23:59:59+00:00","last_seen":"2023-09-01T23:59:59+00:00","evidence_fact_ids":[115459]}],"lender":[{"display_name":"JAG Multi Investments LLC","detail":"loan","count":4,"first_seen":"2023-01-05T23:59:59+00:00","last_seen":"2023-07-13T23:59:59+00:00","evidence_fact_ids":[131838,131839,187623,187624]},{"display_name":"FirstFire Global Opportunities Fund, LLC","detail":"convertible_notes","count":2,"first_seen":"2023-02-23T23:59:59+00:00","last_seen":"2024-04-11T23:59:59+00:00","evidence_fact_ids":[62139,177101]},{"display_name":"Cedar Advance LLC","detail":"other","count":1,"first_seen":"2023-07-21T23:59:59+00:00","last_seen":"2023-07-21T23:59:59+00:00","evidence_fact_ids":[129412]},{"display_name":"Decathlon Alpha V LP","detail":"loan","count":1,"first_seen":"2023-10-05T23:59:59+00:00","last_seen":"2023-10-05T23:59:59+00:00","evidence_fact_ids":[108299]},{"display_name":"Peak One Opportunity Fund, LP","detail":"convertible_notes","count":1,"first_seen":"2023-02-09T23:59:59+00:00","last_seen":"2023-02-09T23:59:59+00:00","evidence_fact_ids":[180433]},{"display_name":"Steven Shum and entity controlled by Andrea Goren","detail":"loan","count":1,"first_seen":"2022-12-05T23:59:59+00:00","last_seen":"2022-12-05T23:59:59+00:00","evidence_fact_ids":[193070]},{"display_name":"a merchant","detail":"other","count":1,"first_seen":"2023-09-01T23:59:59+00:00","last_seen":"2023-09-01T23:59:59+00:00","evidence_fact_ids":[115461]}],"ma_counterparty":[{"display_name":"NAYA Biosciences, Inc.","detail":"change_of_control","count":2,"first_seen":"2024-10-15T23:59:59+00:00","last_seen":"2024-10-15T23:59:59+00:00","evidence_fact_ids":[111105,111106]},{"display_name":"Family Beginnings P.C.","detail":"acquisition","count":1,"first_seen":"2026-02-24T23:59:59+00:00","last_seen":"2026-02-24T23:59:59+00:00","evidence_fact_ids":[24656]},{"display_name":"Wisconsin Fertility Institute","detail":"acquisition","count":1,"first_seen":"2023-08-11T23:59:59+00:00","last_seen":"2023-08-11T23:59:59+00:00","evidence_fact_ids":[120016]}]},"facts":[{"fact_type":"earnings_release","fact_key":"93fd404e013df61841d135c4b09ec74b8a6cd0e6","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2026-06-22T13:05:10+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$(5.5) million","period_text":"first quarter ended March 31, 2026","report_date":"2026-06-22","result_type":"reported_results","revenue_text":"$2,015,225"},"claim":"INVO Fertility, Inc. reported first quarter ended March 31, 2026 results: revenue $2,015,225, net income $(5.5) million.","evidence_excerpt":"announced financial results for the first quarter ended March 31, 2026. Q1\n2026 Financial Highlights (all metrics compared to Q1 2025 unless otherwise noted) ● Revenue\n was $2,015,225, an increase of 23% compared to $1,637,185. ● Consolidated\n clinic revenue increased 22% to $1,982,233, compared to $1,621,553. ● Net\n loss from continuing operations was $(5.5)","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-26-029517","anchor_url":"https://secwatch.observer/filing/0001493152-26-029517#claim-93fd404e013df61841d135c4b09ec74b8a6cd0e6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226029517/0001493152-26-029517-index.htm"},{"fact_type":"earnings_release","fact_key":"30c826a965e0698bb8910d8fce4dbcd51e52acf4","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2026-06-02T12:40:33+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$(5.3) million","period_text":"fiscal year 2025","report_date":"2026-06-02","result_type":"reported_results","revenue_text":"$6,841,250"},"claim":"INVO Fertility, Inc. reported fiscal year 2025 results: revenue $6,841,250, net income $(5.3) million.","evidence_excerpt":"and technologies,\ntoday announced fiscal year 2025 financial results. FY2025\nFinancial Highlights (all metrics compared to FY2024 unless otherwise noted) ● Revenue\n was $6,841,250, an increase of 5% compared to $6,532,000. ● Consolidated\n clinic revenue increased 4% to $6,721,057, compared to $6,450,431. ● Revenue\n from all clinics was $8,021,929, including","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-026777","anchor_url":"https://secwatch.observer/filing/0001493152-26-026777#claim-30c826a965e0698bb8910d8fce4dbcd51e52acf4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226026777/0001493152-26-026777-index.htm"},{"fact_type":"auditor_change","fact_key":"a8f7a02c3ce70f71e4ca5397e40ca16a22277466","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2026-06-02T12:30:27+00:00","payload":{"action":"non_reliance","auditor_name":null,"disagreement_text":null,"effective_date":"2026-06-01","item_codes_triggered":["4.02"],"non_reliance_signal":"non_reliance","successor_auditor_name":null},"claim":"INVO Fertility, Inc. reported that prior financial statements should not be relied upon.","evidence_excerpt":"On June 1, 2026, the audit committee of the Company, after considering the recommendations of management, concluded that the Company’s previously issued unaudited consolidated financial statements contained within its (i) Quarterly Report on Form 10-Q as of March 31, 2025 and for the three months then ended, filed with the Securities and Exchange Commission (“SEC”) on May 20, 2025, (ii) Quarterly Report on Form 10-Q as of June 30, 2025 and for the three and six months then ended, filed with the SEC on August 14, 2025, and (iii) Quarterly Report on Form 10-Q as of September 30, 2025 and for the three and nine months then ended, filed with the SEC on November 17, 2025 should no longer be relied due the 2025 Financial Statement Errors.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-026772","anchor_url":"https://secwatch.observer/filing/0001493152-26-026772#claim-a8f7a02c3ce70f71e4ca5397e40ca16a22277466","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226026772/0001493152-26-026772-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"2e1e5e76ad948db74277c71712a232e6b4861cbc","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2026-04-29T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2026-06-23","deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2026-04-23","notice_type":"deficiency_notice","plan_due_date":"2026-06-23","raw_rule_text":null,"reported_value":null,"rule_numbers":["5250(c)(1)"],"rules_cited_in_text":true},"claim":"INVO Fertility, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"April 23, 2026, INVO Fertility, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications\nstaff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company failed to fi","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-019593","anchor_url":"https://secwatch.observer/filing/0001493152-26-019593#claim-2e1e5e76ad948db74277c71712a232e6b4861cbc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226019593/0001493152-26-019593-index.htm"},{"fact_type":"governance_change","fact_key":"aab5e05c50ef2dfe9a030b04d5f7df5ebcb17edc","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2026-03-31T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-03-27","item_codes_triggered":["5.03"],"summary_text":"Filed a Certificate of Change with the Nevada Secretary of State to effectuate a 1-for-5 reverse stock split of common stock"},"claim":"INVO Fertility, Inc.: Filed a Certificate of Change with the Nevada Secretary of State to effectuate a 1-for-5 reverse stock split of common stock (effective 2026-03-27).","evidence_excerpt":"On March 25, 2026, INVO Fertility, Inc. (the “Company”) filed a Certificate of Change (the “Certificate of Change”) with the Secretary of State of the State of Nevada to effectuate a 1-for-5 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding and authorized shares of common stock, par value $0.0001 per share (“Common Stock”). The Reverse Stock Split became effective at 12:01 a.m., Eastern Time, on Friday, March 27, 2026","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-014227","anchor_url":"https://secwatch.observer/filing/0001493152-26-014227#claim-aab5e05c50ef2dfe9a030b04d5f7df5ebcb17edc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226014227/0001493152-26-014227-index.htm"},{"fact_type":"equity_issuance","fact_key":"3e236304a6127983722d02a60b4ed73ee7e9b393","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2026-02-24T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":null,"effective_date":"2026-02-18","item_codes_triggered":["3.02"],"purchaser":"the Seller","security_type":"preferred_stock","shares_text":"400 shares of the Company's Series D Non-Voting Convertible Preferred Stock"},"claim":"INVO Fertility, Inc. issued 400 shares of the Company's Series D Non-Voting Convertible Preferred Stock of preferred stock to the Seller.","evidence_excerpt":"On February 18, 2026, the Company issued 400 shares of the Company's Series D Non-Voting Convertible Preferred Stock (the \"Series D Preferred\") to the Seller.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-26-007830","anchor_url":"https://secwatch.observer/filing/0001493152-26-007830#claim-3e236304a6127983722d02a60b4ed73ee7e9b393","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226007830/0001493152-26-007830-index.htm"},{"fact_type":"governance_change","fact_key":"3039af7434f4a4bfee7dcc71812c5547c561b313","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2026-02-24T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-02-18","item_codes_triggered":["5.03"],"summary_text":"Filed Series D Certificate of Designation to establish rights, preferences, and privileges of Series D Preferred Stock"},"claim":"INVO Fertility, Inc.: Filed Series D Certificate of Designation to establish rights, preferences, and privileges of Series D Preferred Stock (effective 2026-02-18).","evidence_excerpt":"On February 18, 2026, we filed with the Nevada Secretary of State the Series D Certificate of Designation, which sets forth the rights, preferences, and privileges of the Series D Preferred.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-007830","anchor_url":"https://secwatch.observer/filing/0001493152-26-007830#claim-3039af7434f4a4bfee7dcc71812c5547c561b313","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226007830/0001493152-26-007830-index.htm"},{"fact_type":"ma_transaction","fact_key":"08d3b5175031293771172b78cd5ed220ea672e75","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2026-02-24T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2026-02-18","consideration_text":"$760,000","counterparty":"Family Beginnings P.C. (the Clinic)","effective_date":"2026-02-18","item_codes_triggered":["2.01"]},"claim":"INVO Fertility, Inc. completed an acquisition involving Family Beginnings P.C. (the Clinic) for $760,000 (closed 2026-02-18).","evidence_excerpt":"On February 18, 2026, the Company, through Buyer, consummated its acquisition (the “Acquisition”) of Family Beginnings P.C. (the “Clinic”) for a combined purchase price of $760,000, of which $360,000 was paid in cash on the closing date (a net amount of $210,000 after a $150,000 holdback) and $400,000 was paid on the closing date in 400 shares of the Company’s Series D Preferred","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-007830","anchor_url":"https://secwatch.observer/filing/0001493152-26-007830#claim-08d3b5175031293771172b78cd5ed220ea672e75","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226007830/0001493152-26-007830-index.htm"},{"fact_type":"equity_issuance","fact_key":"41ce29f7375d5c1a8f071e61ac25ac3bcdee3fca","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2026-01-30T23:59:59+00:00","payload":{"action":"warrant_issuance","consideration_text":"The holder agreed to exercise the Existing Warrants for cash at a reduced exercise price of $1.59 per share, resulting in gross proceeds of approximately $7.5 m","effective_date":"2026-01-30","item_codes_triggered":["3.02"],"purchaser":"institutional investor","security_type":"warrant","shares_text":"9,467,456 shares of Common Stock"},"claim":"INVO Fertility, Inc. issued 9,467,456 shares of Common Stock of warrant to institutional investor for The holder agreed to exercise the Existing Warrants for cash at a reduced exercise price of $1.59 per share, resulting in gross proceeds of approximately $7.5 m.","evidence_excerpt":"(the “SEC”) on December\n29, 2025. Pursuant\nto the Inducement Letter Agreement, the Holder agreed to exercise the Existing Warrants for cash at a reduced exercise price of $1.59\nper share in consideration for the Company’s agreement to issue new unregistered warrants to purchase up to an aggregate of 9,467,456\nshares of Common Stock at an exercise price","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-004484","anchor_url":"https://secwatch.observer/filing/0001493152-26-004484#claim-41ce29f7375d5c1a8f071e61ac25ac3bcdee3fca","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226004484/0001493152-26-004484-index.htm"},{"fact_type":"material_agreement","fact_key":"a3073cd0bc102a56f0592bc59533af3ddc77a47b","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2026-01-30T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Inducement Letter Agreement","agreement_type":"equity_purchase","counterparty":"an institutional investor and existing holder","effective_date":"2026-01-28","item_codes_triggered":["1.01"],"value_text":"approximately $7.5 million"},"claim":"INVO Fertility, Inc. entered into Inducement Letter Agreement with an institutional investor and existing holder valued at approximately $7.5 million (effective 2026-01-28).","evidence_excerpt":"On January 28, 2026, INVO Fertility, Inc. (the “Company”) entered into an inducement letter agreement (the “Inducement Letter Agreement”) with an institutional investor and existing holder (the “Holder”) of certain existing warrants (the “Existing Warrants”) to purchase up to 4,733,728 shares of the Company’s common stock (the “Common Stock”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-004484","anchor_url":"https://secwatch.observer/filing/0001493152-26-004484#claim-a3073cd0bc102a56f0592bc59533af3ddc77a47b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226004484/0001493152-26-004484-index.htm"},{"fact_type":"governance_change","fact_key":"87bf3ffa9c75c859bdb4fdb17431e8f116321cdc","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2026-01-26T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-01-22","item_codes_triggered":["5.03"],"summary_text":"Increased authorized shares of common stock from 6,250,000 to 250,000,000"},"claim":"INVO Fertility, Inc.: Increased authorized shares of common stock from 6,250,000 to 250,000,000 (effective 2026-01-22).","evidence_excerpt":"On January 22, 2026, the Company filed a Certificate of Amendment (the “Amendment”) to its Articles of Incorporation to increase its authorized shares of common stock from 6,250,000 shares to 250,000,000 shares.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-003628","anchor_url":"https://secwatch.observer/filing/0001493152-26-003628#claim-87bf3ffa9c75c859bdb4fdb17431e8f116321cdc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226003628/0001493152-26-003628-index.htm"},{"fact_type":"material_agreement","fact_key":"03544a4ee27198d8181bf40cf86d78cd125b2daa","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2025-12-17T23:59:59+00:00","payload":{"action":"entry","agreement_name":"APA","agreement_type":"asset_purchase","counterparty":"Family Beginnings, P.C. and James Donahue MD","effective_date":"2025-12-15","item_codes_triggered":["1.01"],"value_text":"combined purchase price of $750,000"},"claim":"INVO Fertility, Inc. entered into APA with Family Beginnings, P.C. and James Donahue MD valued at combined purchase price of $750,000 (effective 2025-12-15).","evidence_excerpt":"entered into an asset purchase agreement by and among the Buyer, Family Beginnings, P.C., an Indiana professional service corporation (the \"Seller\"), and James Donahue MD (\"Dr. Donahue\") (the \"APA\") to acquire the non-clinical assets of the Seller’s owned and operated fertility clinic in Indianapolis, Indiana (the \"Clinic\") for a combined purchase price of $750,000","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001493152-25-028070","anchor_url":"https://secwatch.observer/filing/0001493152-25-028070#claim-03544a4ee27198d8181bf40cf86d78cd125b2daa","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315225028070/0001493152-25-028070-index.htm"},{"fact_type":"material_agreement","fact_key":"ce3bd7a7efc5fffb6905b3c72469c156ae21d1a4","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2025-12-05T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Registration Rights Agreement","agreement_type":"equity_purchase","counterparty":"institutional investor","effective_date":"2025-12-02","item_codes_triggered":["1.01"],"value_text":null},"claim":"INVO Fertility, Inc. entered into Registration Rights Agreement with institutional investor (effective 2025-12-02).","evidence_excerpt":"Further, in connection with the Private Placement, on December 2, 2025, the Company entered into that certain registration rights agreement (the “Registration Rights Agreement”), by and among the Company and the Purchaser, pursuant to which the Company agreed, among other things, to prepare and file with the Securities and Exchange Commission a Registration Statement","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-026427","anchor_url":"https://secwatch.observer/filing/0001493152-25-026427#claim-ce3bd7a7efc5fffb6905b3c72469c156ae21d1a4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315225026427/0001493152-25-026427-index.htm"},{"fact_type":"material_agreement","fact_key":"a0af2f08ba9d7645dd9556a4696ff0bd38916702","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2025-12-05T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Placement Agency Agreement","agreement_type":"underwriting","counterparty":"Maxim Group LLC","effective_date":"2025-12-02","item_codes_triggered":["1.01"],"value_text":null},"claim":"INVO Fertility, Inc. entered into Placement Agency Agreement with Maxim Group LLC (effective 2025-12-02).","evidence_excerpt":"Also in connection with the Private Placement, on December 2, 2025, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC (the “Placement Agent”), pursuant to which (i) the Placement Agent agreed to act as exclusive placement agent on a “reasonable best efforts” basis in connection with the Private Placement","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-026427","anchor_url":"https://secwatch.observer/filing/0001493152-25-026427#claim-a0af2f08ba9d7645dd9556a4696ff0bd38916702","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315225026427/0001493152-25-026427-index.htm"},{"fact_type":"material_agreement","fact_key":"2136f1a194530ac9a43c165607b67c685af5f1d0","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2025-12-05T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"institutional investor","effective_date":"2025-12-02","item_codes_triggered":["1.01"],"value_text":"approximately $4,000,000"},"claim":"INVO Fertility, Inc. entered into Securities Purchase Agreement with institutional investor valued at approximately $4,000,000 (effective 2025-12-02).","evidence_excerpt":"On December 2, 2025, INVO Fertility, Inc., a Nevada corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with an institutional investor (the “Purchaser”), pursuant to which the Company agreed to issue and sell securities of the Company, in the aggregate amount of approximately $4,000,000","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-026427","anchor_url":"https://secwatch.observer/filing/0001493152-25-026427#claim-2136f1a194530ac9a43c165607b67c685af5f1d0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315225026427/0001493152-25-026427-index.htm"},{"fact_type":"equity_issuance","fact_key":"ccef37bbce96e3aa5af420f14a3be218c84f90f6","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2025-12-05T23:59:59+00:00","payload":{"action":"warrant_issuance","consideration_text":"acting as placement agent","effective_date":"2025-12-02","item_codes_triggered":["3.02"],"purchaser":"placement agent","security_type":"warrant","shares_text":"warrants to purchase up to 118,343 shares of Common Stock"},"claim":"INVO Fertility, Inc. issued warrants to purchase up to 118,343 shares of Common Stock of warrant to placement agent for acting as placement agent.","evidence_excerpt":"the Company agreed to pay the Placement Agent an aggregate fee equal to 8.0% of the gross proceeds raised in the Private Placement and warrants to purchase up to 118,343 shares of Common Stock at an exercise price of $2.1125 per share (the \"Placement Agent Warrants\").","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001493152-25-026427","anchor_url":"https://secwatch.observer/filing/0001493152-25-026427#claim-ccef37bbce96e3aa5af420f14a3be218c84f90f6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315225026427/0001493152-25-026427-index.htm"},{"fact_type":"equity_issuance","fact_key":"1ad3de2ce0b8ed442b0e55331363707e7de521c2","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2025-12-05T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"gross proceeds of approximately $4,000,000","effective_date":"2025-12-02","item_codes_triggered":["3.02"],"purchaser":"institutional investor","security_type":"warrant","shares_text":"prefunded common stock purchase warrants to purchase 2,131,864 shares of Common Stock, and common stock purchase warrants to purchase 4,733,728 shares of Common"},"claim":"INVO Fertility, Inc. issued prefunded common stock purchase warrants to purchase 2,131,864 shares of Common Stock, and common stock purchase warrants to purchase 4,733,728 shares of Common of warrant to institutional investor for gross proceeds of approximately $4,000,000.","evidence_excerpt":"On December 2, 2025, INVO Fertility, Inc., a Nevada corporation (the \"Company\"), entered into a securities purchase agreement (the \"Securities Purchase Agreement\") with an institutional investor (the \"Purchaser\"), pursuant to which the Company agreed to issue and sell securities of the Company, in the aggregate amount of approximately $4,000,000, comprised of 235,000 shares (the \"Shares\") of common stock par value $0.0001 per share (the \"Common Stock\"), prefunded common stock purchase warrants to purchase 2,131,864 shares of Common Stock (the \"Pre-Funded Warrants\"), and common stock purchase warrants to purchase 4,733,728 shares of Common Stock (the \"Common Warrants\"), to the Purchaser in a private placement (the \"Private Placement\").","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001493152-25-026427","anchor_url":"https://secwatch.observer/filing/0001493152-25-026427#claim-1ad3de2ce0b8ed442b0e55331363707e7de521c2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315225026427/0001493152-25-026427-index.htm"},{"fact_type":"equity_issuance","fact_key":"8d1fb960cac5c6c04c2fe34b92b51499fa2971ff","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2025-12-05T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"gross proceeds of approximately $4,000,000","effective_date":"2025-12-02","item_codes_triggered":["3.02"],"purchaser":"institutional investor","security_type":"common_stock","shares_text":"235,000 shares of common stock"},"claim":"INVO Fertility, Inc. issued 235,000 shares of common stock of common stock to institutional investor for gross proceeds of approximately $4,000,000.","evidence_excerpt":"On December 2, 2025, INVO Fertility, Inc., a Nevada corporation (the \"Company\"), entered into a securities purchase agreement (the \"Securities Purchase Agreement\") with an institutional investor (the \"Purchaser\"), pursuant to which the Company agreed to issue and sell securities of the Company, in the aggregate amount of approximately $4,000,000, comprised of 235,000 shares (the \"Shares\") of common stock par value $0.0001 per share (the \"Common Stock\"), prefunded common stock purchase warrants to purchase 2,131,864 shares of Common Stock (the \"Pre-Funded Warrants\"), and common stock purchase warrants to purchase 4,733,728 shares of Common Stock (the \"Common Warrants\"), to the Purchaser in a private placement (the \"Private Placement\").","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001493152-25-026427","anchor_url":"https://secwatch.observer/filing/0001493152-25-026427#claim-8d1fb960cac5c6c04c2fe34b92b51499fa2971ff","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315225026427/0001493152-25-026427-index.htm"},{"fact_type":"governance_change","fact_key":"f40487441e9c270c5fc7a0373866e6be77c92c8d","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2025-12-03T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-11-28","item_codes_triggered":["5.03"],"summary_text":"1-for-8 reverse stock split of common stock and reduction in authorized shares from 50,000,000 to 6,250,000, effected by filing a Certificate of Change with the Nevada Secretary of State"},"claim":"INVO Fertility, Inc.: 1-for-8 reverse stock split of common stock and reduction in authorized shares from 50,000,000 to 6,250,000, effected by filing a Certificate of Change with the Nevada Secretary of State (effective 2025-11-28).","evidence_excerpt":"On November 26, 2025, the Company filed a Certificate of Change (the “Certificate of Change”) with the Secretary of State of the State of Nevada to effectuate a 1-for-8 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding and authorized shares of Common Stock.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-025977","anchor_url":"https://secwatch.observer/filing/0001493152-25-025977#claim-f40487441e9c270c5fc7a0373866e6be77c92c8d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315225025977/0001493152-25-025977-index.htm"},{"fact_type":"equity_issuance","fact_key":"acb18f99075f917127b0a430aec11ec3bf1bf11d","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2025-10-22T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"$500,000 in cash","effective_date":"2025-10-16","item_codes_triggered":["3.02"],"purchaser":"an institutional investor and existing holder","security_type":"preferred_stock","shares_text":"500 shares of C-2 Preferred"},"claim":"INVO Fertility, Inc. issued 500 shares of C-2 Preferred of preferred stock to an institutional investor and existing holder for $500,000 in cash.","evidence_excerpt":"a party pursuant to a joinder agreement (the “ Joinder Agreement ”) on October 11, 2024), to acquire 500 shares\nof C-2 Preferred, with an aggregate stated value of $500,000, for $500,000 in cash. As a result of the exercise, the conversion price\non the C-2 Preferred adjusted to $0.6285 per share. The C-2 Preferred issued pursuant to this exercise were","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-018911","anchor_url":"https://secwatch.observer/filing/0001493152-25-018911#claim-acb18f99075f917127b0a430aec11ec3bf1bf11d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315225018911/0001493152-25-018911-index.htm"},{"fact_type":"equity_issuance","fact_key":"c3996a689408b6abecfdef4d79dbf5db3a6e4046","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2025-10-10T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"$200,000 in cash","effective_date":"2025-10-06","item_codes_triggered":["3.02"],"purchaser":"an institutional investor and existing holder","security_type":"preferred_stock","shares_text":"200 shares of C-2 Preferred"},"claim":"INVO Fertility, Inc. issued 200 shares of C-2 Preferred of preferred stock to an institutional investor and existing holder for $200,000 in cash.","evidence_excerpt":"to acquire 200 shares of C-2 Preferred, with an aggregate stated value of $200,000, for $200,000 in cash.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-25-017752","anchor_url":"https://secwatch.observer/filing/0001493152-25-017752#claim-c3996a689408b6abecfdef4d79dbf5db3a6e4046","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315225017752/0001493152-25-017752-index.htm"},{"fact_type":"equity_issuance","fact_key":"7e847d2d008a57d57fef8e0acf6cfa228972affd","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2025-10-03T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"$400,000","effective_date":"2025-09-30","item_codes_triggered":["3.02"],"purchaser":"an institutional investor and existing holder","security_type":"preferred_stock","shares_text":"400 shares of C-2 Preferred"},"claim":"INVO Fertility, Inc. issued 400 shares of C-2 Preferred of preferred stock to an institutional investor and existing holder for $400,000.","evidence_excerpt":"became a party pursuant to a joinder agreement\n(the “ Joinder Agreement ”) on October 11, 2024), to acquire 400 shares of C-2 Preferred, with an aggregate stated value\nof $400,000, for $400,000 in cash. As a result of the exercise, the conversion price on the C-2 Preferred adjusted to $0.7141 per share.\nThe C-2 Preferred issued pursuant to this exercise were","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-016850","anchor_url":"https://secwatch.observer/filing/0001493152-25-016850#claim-7e847d2d008a57d57fef8e0acf6cfa228972affd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315225016850/0001493152-25-016850-index.htm"},{"fact_type":"equity_issuance","fact_key":"e36a4b305f3f24131f99e895ada02fbb10ce0cde","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2025-09-29T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"aggregated stated value of 1,334,000","effective_date":"2025-09-29","item_codes_triggered":["3.02"],"purchaser":"Five Narrow Lane LP","security_type":"preferred_stock","shares_text":"467 additional shares of Series C-2 Preferred Stock"},"claim":"INVO Fertility, Inc. issued 467 additional shares of Series C-2 Preferred Stock of preferred stock to Five Narrow Lane LP for aggregated stated value of 1,334,000.","evidence_excerpt":"the Company and Five Narrow Lane LP, a Delaware limited partnership (“ FNL ”) entered into an agreement (the “ Exchange Agreement ”) pursuant to which FNL agreed to exchange a Second Amended and Restated Senior Secured Convertible Debenture Due February 11, 2026 (the “ Second Amended and Restated Debenture ”) held by FNL for receipt of shares of Series C-2 Convertible Preferred Stock (the “ Series C-2 Preferred Stock ”) with an aggregated stated value of 1,334,000. In consideration thereof, the Company agreed to issue 467 additional shares of Series C-2 Preferred Stock to FNL.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-016076","anchor_url":"https://secwatch.observer/filing/0001493152-25-016076#claim-e36a4b305f3f24131f99e895ada02fbb10ce0cde","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315225016076/0001493152-25-016076-index.htm"},{"fact_type":"equity_issuance","fact_key":"ef7495eb77f6990925347d03066f76813e63f2dd","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2025-09-12T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"$200,000 in cash","effective_date":"2025-09-08","item_codes_triggered":["3.02"],"purchaser":"an institutional investor and existing holder (the “Holder”)","security_type":"preferred_stock","shares_text":"200 shares of C-2 Preferred"},"claim":"INVO Fertility, Inc. issued 200 shares of C-2 Preferred of preferred stock to an institutional investor and existing holder (the “Holder”) for $200,000 in cash.","evidence_excerpt":"to acquire 200 shares of C-2 Preferred, with an aggregate stated value of $200,000, for $200,000 in cash.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001641172-25-027201","anchor_url":"https://secwatch.observer/filing/0001641172-25-027201#claim-ef7495eb77f6990925347d03066f76813e63f2dd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000164117225027201/0001641172-25-027201-index.htm"},{"fact_type":"auditor_change","fact_key":"8f5932194566b7bf3d82e1128a0d69821909091d","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2025-09-05T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"WithumSmith+Brown, PC","disagreement_text":null,"effective_date":"2025-09-05","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"INVO Fertility, Inc. engaged WithumSmith+Brown, PC as its auditor.","evidence_excerpt":"On September 5, 2025, the Audit Committee approved the engagement of WithumSmith+Brown, PC (“Withum”) effective immediately as the Company’s independent registered public accounting firm to audit the Company’s consolidated financial statements for the year ending December 31, 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001641172-25-026757","anchor_url":"https://secwatch.observer/filing/0001641172-25-026757#claim-8f5932194566b7bf3d82e1128a0d69821909091d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000164117225026757/0001641172-25-026757-index.htm"},{"fact_type":"auditor_change","fact_key":"867df88c989636bec11d7fcea30a3fb8473cf661","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2025-09-05T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"M&K CPAS, PLLC","disagreement_text":null,"effective_date":"2025-09-05","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":"WithumSmith+Brown, PC"},"claim":"INVO Fertility, Inc. dismissed M&K CPAS, PLLC as its auditor.","evidence_excerpt":"On September 3, 2025, INVO Fertility, Inc. (the “Company”) notified M&K CPAS, PLLC (“M&K”) of its dismissal, effective September 5, 2025, as the Company’s independent registered accounting firm.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001641172-25-026757","anchor_url":"https://secwatch.observer/filing/0001641172-25-026757#claim-867df88c989636bec11d7fcea30a3fb8473cf661","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000164117225026757/0001641172-25-026757-index.htm"},{"fact_type":"governance_change","fact_key":"7e616136ec3823b0c44fd34569b7bed28abc37a5","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2025-07-21T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-07-21","item_codes_triggered":["5.03"],"summary_text":"1-for-3 reverse stock split of common stock, with proportionate reduction in authorized shares and adjustments to options/warrants"},"claim":"INVO Fertility, Inc.: 1-for-3 reverse stock split of common stock, with proportionate reduction in authorized shares and adjustments to options/warrants (effective 2025-07-21).","evidence_excerpt":"On July 18, 2025, INVO Fertility, Inc. (the “Company”) filed a Certificate of Change (the “Certificate of Change”) with the Secretary of State of the State of Nevada to effectuate a 1-for-3 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding and authorized shares of common stock, par value $0.0001 per share (“Common Stock”). The Reverse Stock Split became effective at 12:01 a.m., Eastern Time, on Monday, July 21, 2025","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001641172-25-020406","anchor_url":"https://secwatch.observer/filing/0001641172-25-020406#claim-7e616136ec3823b0c44fd34569b7bed28abc37a5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000164117225020406/0001641172-25-020406-index.htm"},{"fact_type":"governance_change","fact_key":"39a206341d6188916aa7563dcd6fd9bc247ae75b","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2025-07-01T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-06-27","item_codes_triggered":["5.03"],"summary_text":"Filed Certificate of Amendment to Certificate of Designation of Series C-2 Convertible Preferred Stock, amending rights, preferences, and privileges of the C-2 Preferred, authorizing 20,000 shares with a stated value of $1,000 per share, adjusting conversion price, and setting dividend and liquidati"},"claim":"INVO Fertility, Inc.: Filed Certificate of Amendment to Certificate of Designation of Series C-2 Convertible Preferred Stock, amending rights, preferences, and privileges of the C-2 Preferred, authorizing 20,000 shares with a stated value of $1,000 per share, adjusting conversion price, and setting dividend and liquidati (effective 2025-06-27).","evidence_excerpt":"On June 27, 2025, we filed with the Nevada Secretary of State a Certificate of Amendment to Certificate of Designation of the Series C-2 Non-Voting Convertible Preferred Stock of the Company (the “ Certificate of Amendment ”), which amends and restates the rights, preferences, and privileges of the C-2 Preferred.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001641172-25-017280","anchor_url":"https://secwatch.observer/filing/0001641172-25-017280#claim-39a206341d6188916aa7563dcd6fd9bc247ae75b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000164117225017280/0001641172-25-017280-index.htm"},{"fact_type":"ma_transaction","fact_key":"0607ed9cab2a3cce94fe88ba344797ecc8bc9f84","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2025-06-06T23:59:59+00:00","payload":{"action":"disposition","closing_date":"2025-06-02","consideration_text":null,"counterparty":null,"effective_date":"2025-06-02","item_codes_triggered":["2.01"]},"claim":"INVO Fertility, Inc. completed a disposition (closed 2025-06-02).","evidence_excerpt":"Effective June 2, 2025, INVO Fertility, Inc., a Nevada corporation (the “ Company ”) consummated the divestiture of a majority of its holdings in NAYA Therapeutics Inc., a Delaware Corporation (“ NTI ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001641172-25-014019","anchor_url":"https://secwatch.observer/filing/0001641172-25-014019#claim-0607ed9cab2a3cce94fe88ba344797ecc8bc9f84","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000164117225014019/0001641172-25-014019-index.htm"},{"fact_type":"executive_change","fact_key":"a32a55b5fb","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2025-05-30T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-05-28","interim":false,"role":"President","role_category":"president","successor_name":null,"successor_named":false},"claim":"Dr. Daniel Teper resigned as President at INVO Fertility, Inc..","evidence_excerpt":"On May 28, 2025, Dr. Daniel Teper resigned as President of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001641172-25-013122","anchor_url":"https://secwatch.observer/filing/0001641172-25-013122#claim-a32a55b5fb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000164117225013122/0001641172-25-013122-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"8278d1ab6189310617c528a14923bb3f35fbb747","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2025-04-18T23:59:59+00:00","payload":{"company_response":"expects to submit Filing as soon as practicable","compliance_status":"deficient","cure_deadline":null,"deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-04-16","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5250(c)(1)","reported_value":null,"rule_numbers":["5250(c)(1)"],"rules_cited_in_text":true},"claim":"INVO Fertility, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"April 16, 2025, INVO Fertility, Inc. (the “Company”),\nformerly known as NAYA Biosciences, Inc., received a letter (the “Letter”) from the Listing Qualifications staff (the “Staff”)\nof The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company failed to file its Annual Report on Form 10-K for the\nyear ended December 31, 2024 (the “Filing”), on a timely basis and, as such, no longer satisfies Nasdaq Listing Rule 5250(c)(1)\n(the “Rule”). The Letter has no immediate effect on the listing\nof the Company’s common stock and the Company’s common stock continues to trade on The Nasdaq Capital M","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001641172-25-005359","anchor_url":"https://secwatch.observer/filing/0001641172-25-005359#claim-8278d1ab6189310617c528a14923bb3f35fbb747","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000164117225005359/0001641172-25-005359-index.htm"},{"fact_type":"governance_change","fact_key":"f3e780f647539edf369d58fb748334b333215b0b","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2025-04-18T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-04-14","item_codes_triggered":["5.03"],"summary_text":"Company changed its corporate name to INVO Fertility, Inc. via an Amendment to Articles of Incorporation filed with Nevada Secretary of State on April 14, 2025."},"claim":"INVO Fertility, Inc.: Company changed its corporate name to INVO Fertility, Inc. via an Amendment to Articles of Incorporation filed with Nevada Secretary of State on April 14, 2025 (effective 2025-04-14).","evidence_excerpt":"On April 14, 2025, the Company changed its corporate name to INVO Fertility, Inc., pursuant to an Amendment to Articles of Incorporation filed with the Nevada Secretary of State on April 14, 2025 (the “Name Change”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001641172-25-005359","anchor_url":"https://secwatch.observer/filing/0001641172-25-005359#claim-f3e780f647539edf369d58fb748334b333215b0b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000164117225005359/0001641172-25-005359-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"d3eecb857b715c817c794d8d081c1bbd87f710be","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2025-03-31T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"regained_compliance","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-03-31","notice_type":"compliance_regained","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"INVO Fertility, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"March 31, 2025, the Company evidenced a closing bid price of at least $1.00 per share for 10 consecutive\nbusiness days and, on March 31, 2025, the Staff determined that the Company has regained compliance with the Rule. Accordingly, the Company’s\nsecurities are no longer subject to delisting and the listing matter has been closed.","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001641172-25-001807","anchor_url":"https://secwatch.observer/filing/0001641172-25-001807#claim-d3eecb857b715c817c794d8d081c1bbd87f710be","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000164117225001807/0001641172-25-001807-index.htm"},{"fact_type":"governance_change","fact_key":"df3e2df0fae04f7324e70f1ea04ca872a7789d9c","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2025-03-24T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-03-18","item_codes_triggered":["5.03"],"summary_text":"Amended certificate of incorporation to effect a 1-for-12 reverse stock split of common stock and adjust authorized shares from 50,000,000 to 4,166,667."},"claim":"INVO Fertility, Inc.: Amended certificate of incorporation to effect a 1-for-12 reverse stock split of common stock and adjust authorized shares from 50,000,000 to 4,166,667 (effective 2025-03-18).","evidence_excerpt":"On March 18, 2025, NAYA Biosciences, Inc. (the “Company”) filed a Certificate of Change (the “Certificate of Change”) with the Secretary of State of the State of Nevada to effectuate a 1-for-12 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding and authorized shares of common stock, par value $0.0001 per share (“Common Stock”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001641172-25-000316","anchor_url":"https://secwatch.observer/filing/0001641172-25-000316#claim-df3e2df0fae04f7324e70f1ea04ca872a7789d9c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000164117225000316/0001641172-25-000316-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"2edaebdb18ddd265806461125bd13ef97d343386","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2025-01-16T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"plan_due","cure_deadline":"2025-06-30","deficiency_type":"other","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-01-10","notice_type":"deficiency_notice","plan_due_date":"2025-02-24","raw_rule_text":"Nasdaq Listing Rules 5620(a) and 5801(s)(2)(G)","reported_value":null,"rule_numbers":["5620(a)","5801(s)(2)(G)"],"rules_cited_in_text":true},"claim":"INVO Fertility, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5801(s)(2)(G)).","evidence_excerpt":"January 10, 2025, the Company received notice (the “Notice”) from the staff (the “Staff”) of The Nasdaq Stock\nMarket LLC (“Nasdaq”) advising the Company that it no longer complies with Nasdaq Listing Rules 5620(a) and 5801(s)(2)(G)\nthat require companies listed on The Nasdaq Capital Market to hold an annual meeting of shareholders (an “ASM”) within twelve\nmonths of the fiscal year’s end (the “ASM Rule”). The Company did not hold an ASM in its fiscal year ended December\n31, 2024. The Notice has no immediate effect on the listing of the Company’s common stock and the Company’s common stock\nconti","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-25-002543","anchor_url":"https://secwatch.observer/filing/0001493152-25-002543#claim-2edaebdb18ddd265806461125bd13ef97d343386","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315225002543/0001493152-25-002543-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"2edaebdb18ddd265806461125bd13ef97d343386","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2025-01-16T23:59:59+00:00","payload":{"company_response":"Company intends to hold annual meeting in March 2025 and plans to timely submit plan to Nasdaq.","compliance_status":"deficient","cure_deadline":null,"deficiency_type":"other","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":null,"notice_date":"2025-01-10","notice_type":"deficiency_notice","plan_due_date":"2025-02-24","raw_rule_text":null,"reported_value":null,"rule_numbers":["5620(a)","5801(s)(2)(G)"]},"claim":"INVO Fertility, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5801(s)(2)(G)).","evidence_excerpt":"January 10, 2025, the Company received notice (the “Notice”) from the staff (the “Staff”) of The Nasdaq Stock\nMarket LLC (“Nasdaq”) advising the Company that it no longer complies with Nasdaq Listing Rules 5620(a) and 58","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-002543","anchor_url":"https://secwatch.observer/filing/0001493152-25-002543#claim-2edaebdb18ddd265806461125bd13ef97d343386","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315225002543/0001493152-25-002543-index.htm"},{"fact_type":"governance_change","fact_key":"bf5e91ae07eaac130ddeec14f6eda1355020b424","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2024-10-15T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-10-15","item_codes_triggered":["5.03"],"summary_text":"Company changed its corporate name to NAYA Biosciences, Inc. via an Amendment to Articles of Incorporation."},"claim":"INVO Fertility, Inc.: Company changed its corporate name to NAYA Biosciences, Inc. via an Amendment to Articles of Incorporation (effective 2024-10-15).","evidence_excerpt":"On October 15, 2024, the Company changed its corporate name to NAYA Biosciences, Inc., pursuant to an Amendment to Articles of Incorporation filed with the Nevada Secretary of State on October 15, 2024 (the “ Name Change ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-041062","anchor_url":"https://secwatch.observer/filing/0001493152-24-041062#claim-bf5e91ae07eaac130ddeec14f6eda1355020b424","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224041062/0001493152-24-041062-index.htm"},{"fact_type":"ma_transaction","fact_key":"a480a1ce1841ab9907a1366536d28e88c570c1c4","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2024-10-15T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2024-10-11","consideration_text":"118,148 shares of the Company's common stock and 30,375 shares of the Company's newly-designated Series C-1 Convertible Preferred Stock","counterparty":"NAYA Biosciences, Inc.","effective_date":"2024-10-11","item_codes_triggered":["2.01","5.01"]},"claim":"INVO Fertility, Inc. completed an acquisition involving NAYA Biosciences, Inc. for 118,148 shares of the Company's common stock and 30,375 shares of the Company's newly-designated Series C-1 Convertible Preferred Stock (closed 2024-10-11).","evidence_excerpt":"f NAYA Biosciences, Inc., a Delaware corporation (“ NAYA ”) pursuant to\nan Amended and Restated Agreement and Plan of Merger by and among the Company, NAYA, and INVO Merger","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001493152-24-041062","anchor_url":"https://secwatch.observer/filing/0001493152-24-041062#claim-a480a1ce1841ab9907a1366536d28e88c570c1c4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224041062/0001493152-24-041062-index.htm"},{"fact_type":"ma_transaction","fact_key":"ee61e4686263cf663ce5392f59e02e07d884f465","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2024-10-15T23:59:59+00:00","payload":{"action":"change_of_control","closing_date":"2024-10-11","consideration_text":"118,148 shares of the Company's common stock and 30,375 shares of the Company's newly-designated Series C-1 Convertible Preferred Stock","counterparty":"NAYA Biosciences, Inc.","effective_date":"2024-10-11","item_codes_triggered":["2.01","5.01"]},"claim":"INVO Fertility, Inc. underwent a change of control involving NAYA Biosciences, Inc. for 118,148 shares of the Company's common stock and 30,375 shares of the Company's newly-designated Series C-1 Convertible Preferred Stock (closed 2024-10-11).","evidence_excerpt":"f NAYA Biosciences, Inc., a Delaware corporation (“ NAYA ”) pursuant to\nan Amended and Restated Agreement and Plan of Merger by and among the Company, NAYA, and INVO Merger","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-041062","anchor_url":"https://secwatch.observer/filing/0001493152-24-041062#claim-ee61e4686263cf663ce5392f59e02e07d884f465","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224041062/0001493152-24-041062-index.htm"},{"fact_type":"executive_change","fact_key":"ffeb9be7bd","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2024-10-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-15","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Lyn Falconio was appointed as Director at INVO Fertility, Inc..","evidence_excerpt":"the Company’s board of directors appointed Dr. Daniel Teper and Lyn Falconio as directors of the Company to fill two vacancies on the board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-041062","anchor_url":"https://secwatch.observer/filing/0001493152-24-041062#claim-ffeb9be7bd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224041062/0001493152-24-041062-index.htm"},{"fact_type":"executive_change","fact_key":"6317aa4a11","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2024-10-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-15","interim":false,"role":"President","role_category":"president","successor_name":null,"successor_named":false},"claim":"Daniel Teper was appointed as President at INVO Fertility, Inc..","evidence_excerpt":"the board of directors appointed Dr. Teper as President of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-041062","anchor_url":"https://secwatch.observer/filing/0001493152-24-041062#claim-6317aa4a11","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224041062/0001493152-24-041062-index.htm"},{"fact_type":"executive_change","fact_key":"bbf27425f5","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2024-10-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-15","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Daniel Teper was appointed as Director at INVO Fertility, Inc..","evidence_excerpt":"the Company’s board of directors appointed Dr. Daniel Teper and Lyn Falconio as directors of the Company to fill two vacancies on the board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-041062","anchor_url":"https://secwatch.observer/filing/0001493152-24-041062#claim-bbf27425f5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224041062/0001493152-24-041062-index.htm"},{"fact_type":"earnings_release","fact_key":"ba7f0763cf4a57710abecab024b0c9e777faa5f0","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2024-05-15T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter of 2024","report_date":"2024-05-15","result_type":"reported_results","revenue_text":null},"claim":"INVO Fertility, Inc. reported financial results for the first quarter of 2024.","evidence_excerpt":"On May 15, 2024, INVO Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the period ended March 31, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-019958","anchor_url":"https://secwatch.observer/filing/0001493152-24-019958#claim-ba7f0763cf4a57710abecab024b0c9e777faa5f0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224019958/0001493152-24-019958-index.htm"},{"fact_type":"material_agreement","fact_key":"dd39cd25cc30d0c1650549ebeb452d8a2ecf369b","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2024-04-19T23:59:59+00:00","payload":{"action":"termination","agreement_name":null,"agreement_type":"lease","counterparty":"Brown Fertility Associates PA","effective_date":"2024-04-19","item_codes_triggered":["1.02"],"value_text":null},"claim":"INVO Fertility, Inc. terminated a lease with Brown Fertility Associates PA (effective 2024-04-19).","evidence_excerpt":"On April 19, 2024, INVO Centers LLC (\"INVO Centers\"), a wholly owned subsidiary of INVO Bioscience, Inc. (the \"Company\"), completed the assignment to Brown Fertility Associates PA (\"Brown Fertility\") of its lease with 4602 North Armenia Ave, LLC (the \"Landlord\"), for the property located at 4602 North Armenia Avenue, Suite 200, Tampa, LLC (the \"Premises\").","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-015388","anchor_url":"https://secwatch.observer/filing/0001493152-24-015388#claim-dd39cd25cc30d0c1650549ebeb452d8a2ecf369b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224015388/0001493152-24-015388-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"3673080fe5e907a07ac66c1d661c145d2fcc51f4","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2024-04-19T23:59:59+00:00","payload":{"company_response":"Company intends to appeal to Nasdaq Hearings Panel","compliance_status":"hearing_requested","cure_deadline":"2024-04-24","deficiency_type":"stockholders_equity","delisting_effective_date":"2024-04-26","exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"2500000","notice_date":"2024-04-17","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":"892825","rule_numbers":["5550(b)(1)"],"rules_cited_in_text":true},"claim":"INVO Fertility, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"April 17, 2024, the Company, having reported, on April 16, 2024, stockholders’ equity of $892,825 in the Form 10-K for the period\nended December 31, 2023, received notice (the “Notice”) from the staff (the “Staff”) of The Nasdaq Stock Market\nLLC (“Nasdaq”) advising the Company that it no longer complies with Nasdaq Listing Rule 5550(b)(1) that requires companies\nlisted on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Equity Rule”). In\na decision dated November 22, 2023, a Nasdaq Hearings Panel (the “Panel”) previously had confirmed that the Company reg","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-015388","anchor_url":"https://secwatch.observer/filing/0001493152-24-015388#claim-3673080fe5e907a07ac66c1d661c145d2fcc51f4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224015388/0001493152-24-015388-index.htm"},{"fact_type":"material_agreement","fact_key":"ab036a1eeee1a2114420994fbd6c49e8eb649b69","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2024-04-17T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment to the Warrant Agent Agreement","agreement_type":"other","counterparty":"Transfer Online, Inc.","effective_date":"2024-04-17","item_codes_triggered":["1.01"],"value_text":null},"claim":"INVO Fertility, Inc. amended Amendment to the Warrant Agent Agreement with Transfer Online, Inc. (effective 2024-04-17).","evidence_excerpt":"On April 17, 2024, the Company and the Warrant Agent entered into an Amendment to the Warrant Agent Agreement (the “Amendment”) to confirm that the Company may adjust the exercise price of the of the Warrants to provide an exercise price per share that is lower than the then-current exercise price of the Warrants.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-015013","anchor_url":"https://secwatch.observer/filing/0001493152-24-015013#claim-ab036a1eeee1a2114420994fbd6c49e8eb649b69","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224015013/0001493152-24-015013-index.htm"},{"fact_type":"earnings_release","fact_key":"44e9ff187b509e62f68836040af808653c58df7f","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2024-04-16T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$(2.0) million","period_text":"the fourth quarter and fiscal year ended December 31, 2023","report_date":"2024-04-16","result_type":"reported_results","revenue_text":"$1,381,754"},"claim":"INVO Fertility, Inc. reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue $1,381,754, net income $(2.0) million.","evidence_excerpt":"INVO Reports Fourth Quarter and Full Year 2023 Financial Results SARASOTA, Fla., April 16, 2024 -- INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the establishment and acquisition of fertility clinics, and with the intravaginal culture (“IVC”) procedure enabled by its INVOcell® medical device, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a business update. Q4 2023 Financial Highlights (all metrics compared to Q4 2022 unless otherwise noted) ● Revenue was $1,381,754, an increase of 397% compared to $278,142. ● Clinic revenue increased 519% to $1,362,938, compared to $220,253. All reported clinic revenue is derived from the Company’s INVO Center in Atlanta, Georgia, and fertility clinic in Madison, Wisconsin which are consolidated in the Company’s financial statements. ● Revenue from all clinics, incl","confidence":0.92,"filing_url":"https://secwatch.observer/filing/0001493152-24-014846","anchor_url":"https://secwatch.observer/filing/0001493152-24-014846#claim-44e9ff187b509e62f68836040af808653c58df7f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224014846/0001493152-24-014846-index.htm"},{"fact_type":"debt_financing","fact_key":"4ecd845e70043cfde6265e74184f1fedcbcd415e","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2024-04-11T23:59:59+00:00","payload":{"counterparty":"FirstFire Global Opportunities Fund, LLC","effective_date":"2024-04-05","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"twelve percent (12%) per annum","item_codes_triggered":["2.03"],"maturity_text":"twelve (12) months from the issue date","principal_text":"$275,000.00"},"claim":"INVO Fertility, Inc. incurred convertible notes of $275,000.00 with FirstFire Global Opportunities Fund, LLC at twelve percent (12%) per annum maturing twelve (12) months from the issue date.","evidence_excerpt":"On April 5, 2024, INVO Bioscience, Inc., a Nevada corporation (the “ Company ”) entered into a purchase agreement (the “ Purchase Agreement ”) with FirstFire Global Opportunities Fund, LLC (the “ Buyer ”), pursuant to which the Buyer agreed to purchase, and the Company agreed to issue and sell, (i) a promissory note with an aggregate principal amount of $275,000.00, which is convertible into shares of the Company’s common stock","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-014353","anchor_url":"https://secwatch.observer/filing/0001493152-24-014353#claim-4ecd845e70043cfde6265e74184f1fedcbcd415e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224014353/0001493152-24-014353-index.htm"},{"fact_type":"material_agreement","fact_key":"9e966f2556a370a5c3f54d813c75ab5bee966888","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2024-04-11T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"equity_purchase","counterparty":"FirstFire Global Opportunities Fund, LLC","effective_date":"2024-04-05","item_codes_triggered":["1.01"],"value_text":"$275,000"},"claim":"INVO Fertility, Inc. entered into Purchase Agreement with FirstFire Global Opportunities Fund, LLC valued at $275,000 (effective 2024-04-05).","evidence_excerpt":"On April 5, 2024, INVO Bioscience, Inc., a Nevada corporation (the “ Company ”) entered into a purchase agreement (the “ Purchase Agreement ”) with FirstFire Global Opportunities Fund, LLC (the “ Buyer ”), pursuant to which the Buyer agreed to purchase, and the Company agreed to issue and sell, (i) a promissory note with an aggregate principal amount of $275,000.00","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-014353","anchor_url":"https://secwatch.observer/filing/0001493152-24-014353#claim-9e966f2556a370a5c3f54d813c75ab5bee966888","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224014353/0001493152-24-014353-index.htm"},{"fact_type":"material_agreement","fact_key":"255244880e15a66b5e33b62f3cf93915123885e6","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2024-04-02T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"equity_purchase","counterparty":"Triton Funds LP","effective_date":"2024-03-27","item_codes_triggered":["1.01"],"value_text":"up to $850,000"},"claim":"INVO Fertility, Inc. entered into Purchase Agreement with Triton Funds LP valued at up to $850,000 (effective 2024-03-27).","evidence_excerpt":"On March 27, 2024, INVO Bioscience, Inc., a Nevada corporation (the “ Company ”) entered into a purchase agreement (the “ Purchase Agreement ”) with Triton Funds LP (“ Triton ”), pursuant to which the Company agreed to sell, and Triton agreed to purchase, upon the Company’s request in one or more transactions, up to 1,000,000 shares of the Company’s common stock, par value $0.0001 per share, providing aggregate gross proceeds to the Company of up to $850,000.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-012858","anchor_url":"https://secwatch.observer/filing/0001493152-24-012858#claim-255244880e15a66b5e33b62f3cf93915123885e6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224012858/0001493152-24-012858-index.htm"},{"fact_type":"material_agreement","fact_key":"921c16b98bd1ec6dab4ddb58cf0877147fdceb69","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2024-04-01T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"equity_purchase","counterparty":"Triton Funds LP","effective_date":"2024-03-27","item_codes_triggered":["1.01"],"value_text":"up to $850,000"},"claim":"INVO Fertility, Inc. entered into Purchase Agreement with Triton Funds LP valued at up to $850,000 (effective 2024-03-27).","evidence_excerpt":"On March 27, 2024, INVO Bioscience, Inc., a Nevada corporation (the “ Company ”) entered into a purchase agreement (the “ Purchase Agreement ”) with Triton Funds LP (“ Triton ”), pursuant to which the Company agreed to sell, and Triton agreed to purchase, upon the Company’s request in one or more transactions, up to 1,000,000 shares of the Company’s common stock, par value $0.0001 per share, providing aggregate gross proceeds to the Company of up to $850,000.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-012342","anchor_url":"https://secwatch.observer/filing/0001493152-24-012342#claim-921c16b98bd1ec6dab4ddb58cf0877147fdceb69","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224012342/0001493152-24-012342-index.htm"},{"fact_type":"debt_financing","fact_key":"524868902d3588000d0d2de4526f8c3d5eaa856c","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2024-03-01T23:59:59+00:00","payload":{"counterparty":"Buyer","effective_date":"2024-02-26","event":"incurrence","instrument_type":"other","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"Until the purchase price has been repaid","principal_text":"$344,925"},"claim":"INVO Fertility, Inc. incurred debt of $344,925 with Buyer maturing Until the purchase price has been repaid.","evidence_excerpt":"On February 26, 2024, INVO Bioscience, Inc. (the “Company”) finalized an Agreement for the Purchase and Sale of Future Receipts (the “Future Receipts Agreement”) with a buyer (the “Buyer”) under which the Buyer purchased $344,925 of our future sales for a gross purchase price of $236,250.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-008576","anchor_url":"https://secwatch.observer/filing/0001493152-24-008576#claim-524868902d3588000d0d2de4526f8c3d5eaa856c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224008576/0001493152-24-008576-index.htm"},{"fact_type":"material_agreement","fact_key":"4be6aad5dd0fbcc396531af676230866fda594a4","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2024-03-01T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Agreement for the Purchase and Sale of Future Receipts","agreement_type":"asset_purchase","counterparty":"Buyer","effective_date":"2024-02-26","item_codes_triggered":["1.01"],"value_text":"$236,250"},"claim":"INVO Fertility, Inc. entered into Agreement for the Purchase and Sale of Future Receipts with Buyer valued at $236,250 (effective 2024-02-26).","evidence_excerpt":"On February 26, 2024, INVO Bioscience, Inc. (the “Company”) finalized an Agreement for the Purchase and Sale of Future Receipts (the “Future Receipts Agreement”) with a buyer (the “Buyer”) under which the Buyer purchased $344,925 of our future sales for a gross purchase price of $236,250.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-008576","anchor_url":"https://secwatch.observer/filing/0001493152-24-008576#claim-4be6aad5dd0fbcc396531af676230866fda594a4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224008576/0001493152-24-008576-index.htm"},{"fact_type":"material_agreement","fact_key":"6bddf0e78ea4ff98c8bea01c1cbb3481f34cd337","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2024-01-10T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Convertible Notes extension","agreement_type":"notes_offering","counterparty":"Required Holders","effective_date":"2023-12-27","item_codes_triggered":["1.01"],"value_text":null},"claim":"INVO Fertility, Inc. amended Convertible Notes extension with Required Holders (effective 2023-12-27).","evidence_excerpt":"As of December 27, 2023, the Company secured written consent by the Required Holders for the Convertible Note maturity date to be extended to June 30, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-001962","anchor_url":"https://secwatch.observer/filing/0001493152-24-001962#claim-6bddf0e78ea4ff98c8bea01c1cbb3481f34cd337","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224001962/0001493152-24-001962-index.htm"},{"fact_type":"material_agreement","fact_key":"e85b1d6e9e5407e31fbb5de41ef2e7260f3adc3d","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2024-01-10T23:59:59+00:00","payload":{"action":"entry","agreement_name":"SPA","agreement_type":"equity_purchase","counterparty":"NAYA","effective_date":"2023-12-29","item_codes_triggered":["1.01"],"value_text":"$5.00 per share"},"claim":"INVO Fertility, Inc. entered into SPA with NAYA valued at $5.00 per share (effective 2023-12-29).","evidence_excerpt":"On December 29, 2023, the Company entered into a securities purchase agreement (the “ SPA ”) with NAYA for NAYA’s purchase of 1,000,000 shares of the Company’s Series A Preferred Stock at a purchase price of $5.00 per share.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-001962","anchor_url":"https://secwatch.observer/filing/0001493152-24-001962#claim-e85b1d6e9e5407e31fbb5de41ef2e7260f3adc3d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224001962/0001493152-24-001962-index.htm"},{"fact_type":"material_agreement","fact_key":"df44e1e8e73fdad49d5fef38b529137994719881","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2024-01-10T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Second Amendment","agreement_type":"merger","counterparty":"NAYA Biosciences, Inc.","effective_date":"2023-12-27","item_codes_triggered":["1.01"],"value_text":null},"claim":"INVO Fertility, Inc. amended Second Amendment with NAYA Biosciences, Inc. (effective 2023-12-27).","evidence_excerpt":"On December 27, 2023, INVO Bioscience, Inc., a Nevada corporation (the “ Company ”) entered into second amendment (“ Second Amendment ”) to the previously announced agreement and plan of merger (the “ Merger Agreement ”) by and among the Company, INVO Merger Sub, Inc. (“ Merger Sub ”), and NAYA Biosciences, Inc., a Delaware corporation (“ NAYA ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-001962","anchor_url":"https://secwatch.observer/filing/0001493152-24-001962#claim-df44e1e8e73fdad49d5fef38b529137994719881","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224001962/0001493152-24-001962-index.htm"},{"fact_type":"material_agreement","fact_key":"224603922dc6d8169138a5ef16d353b9b9d80b54","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2024-01-10T23:59:59+00:00","payload":{"action":"entry","agreement_name":"SPA","agreement_type":"equity_purchase","counterparty":"NAYA Biosciences, Inc.","effective_date":"2023-12-29","item_codes_triggered":["1.01"],"value_text":"$5.00 per share"},"claim":"INVO Fertility, Inc. entered into SPA with NAYA Biosciences, Inc. valued at $5.00 per share (effective 2023-12-29).","evidence_excerpt":"On December 29, 2023, INVO Bioscience, Inc., a Nevada corporation (the “ Company ”) entered into securities purchase agreement (the “ SPA ”) with NAYA Biosciences, Inc., a Delaware corporation (“ NAYA ”) for the purchase of 1,000,000 shares of the Company’s Series A Preferred Stock at a purchase price of $5.00 per share.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-001940","anchor_url":"https://secwatch.observer/filing/0001493152-24-001940#claim-224603922dc6d8169138a5ef16d353b9b9d80b54","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224001940/0001493152-24-001940-index.htm"},{"fact_type":"material_agreement","fact_key":"2ef930c743de66cb5c721411df945e07fddcb5bb","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2024-01-03T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Convertible Notes Extension","agreement_type":"notes_offering","counterparty":"Required Holders of Convertible Notes","effective_date":"2023-12-27","item_codes_triggered":["1.01"],"value_text":"Maturity date extended to June 30, 2024; conversion and warrant exercise price lowered to $2.25"},"claim":"INVO Fertility, Inc. amended Convertible Notes Extension with Required Holders of Convertible Notes valued at Maturity date extended to June 30, 2024; conversion and warrant exercise price lowered to $2.25 (effective 2023-12-27).","evidence_excerpt":"As of December 27, 2023, the Company secured written consent by the Required Holders for the Convertible Note maturity date to be extended to June 30, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-000338","anchor_url":"https://secwatch.observer/filing/0001493152-24-000338#claim-2ef930c743de66cb5c721411df945e07fddcb5bb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224000338/0001493152-24-000338-index.htm"},{"fact_type":"shareholder_vote","fact_key":"9a19b4bf8a5f65eec6fecae9cdd6f8e0da865c68","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-12-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-12-26","outcome":"passed","proposal_text":"Reduction of exercise price for March 2023 private placement warrants from $12.60 per share to $2.85 per share","proposal_type":"other","results":[{"broker_non_votes":"763,010","subject":null,"votes_abstain":"5,583","votes_against":"75,038","votes_for":"108,451","votes_withheld":null}]},"claim":"INVO Fertility, Inc. shareholders approved Reduction of exercise price for March 2023 private placement warrants from $12.60 per share to $2.85 per share at the 2023-12-26 meeting.","evidence_excerpt":"The result of the votes to approve Warrant Exercise Price Reduction was as follows: For Against Abstain Broker Non-Vote 108,451 75,038 5,583 763,010","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-046303","anchor_url":"https://secwatch.observer/filing/0001493152-23-046303#claim-9a19b4bf8a5f65eec6fecae9cdd6f8e0da865c68","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223046303/0001493152-23-046303-index.htm"},{"fact_type":"shareholder_vote","fact_key":"1e09b189c5a0015dddf28e28a9af81d7f5bd25b0","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-12-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-12-26","outcome":"passed","proposal_text":"Ratification of appointment of M&K CPAs PLLC as independent public accountant for fiscal year ending December 31, 2023","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"16,141","votes_against":"55,600","votes_for":"880,341","votes_withheld":null}]},"claim":"INVO Fertility, Inc. shareholders approved Ratification of appointment of M&K CPAs PLLC as independent public accountant for fiscal year ending December 31, 2023 at the 2023-12-26 meeting.","evidence_excerpt":"The result of the votes to approve M&K CPAs PLLC was as follows: For Against Abstain 880,341 55,600 16,141","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-046303","anchor_url":"https://secwatch.observer/filing/0001493152-23-046303#claim-1e09b189c5a0015dddf28e28a9af81d7f5bd25b0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223046303/0001493152-23-046303-index.htm"},{"fact_type":"shareholder_vote","fact_key":"8a21fe473dea10d6bae067a2a98f1574589338e6","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-12-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-12-26","outcome":"passed","proposal_text":"Election of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"763,010","subject":"Steven Shum","votes_abstain":null,"votes_against":null,"votes_for":"161,151","votes_withheld":"27,921"},{"broker_non_votes":"763,010","subject":"Trent Davis","votes_abstain":null,"votes_against":null,"votes_for":"160,948","votes_withheld":"28,124"},{"broker_non_votes":"763,010","subject":"Matthew Szot","votes_abstain":null,"votes_against":null,"votes_for":"160,922","votes_withheld":"28,150"},{"broker_non_votes":"763,010","subject":"Barbara Ryan","votes_abstain":null,"votes_against":null,"votes_for":"161,040","votes_withheld":"28,032"},{"broker_non_votes":"763,010","subject":"Rebecca Messina","votes_abstain":null,"votes_against":null,"votes_for":"162,169","votes_withheld":"26,903"}]},"claim":"INVO Fertility, Inc. shareholders approved Election of Directors at the 2023-12-26 meeting.","evidence_excerpt":"The result of the votes to elect the five directors was as follows: Directors For Withheld Broker Non-Votes Steven Shum 161,151 27,921 763,010 Trent Davis 160,948 28,124 763,010 Matthew Szot 160,922 28,150 763,010 Barbara Ryan 161,040 28,032 763,010 Rebecca Messina 162,169 26,903 763,010","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-046303","anchor_url":"https://secwatch.observer/filing/0001493152-23-046303#claim-8a21fe473dea10d6bae067a2a98f1574589338e6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223046303/0001493152-23-046303-index.htm"},{"fact_type":"material_agreement","fact_key":"6f26fdb2be7d5f8f5207b7bada5d84406218c7b7","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-12-28T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment to Common Stock Purchase Warrant","agreement_type":"equity_purchase","counterparty":"a certain institutional investor","effective_date":"2023-12-28","item_codes_triggered":["1.01"],"value_text":null},"claim":"INVO Fertility, Inc. amended Amendment to Common Stock Purchase Warrant with a certain institutional investor (effective 2023-12-28).","evidence_excerpt":"On December 28, 2023, INVO Bioscience, Inc. (the “Company”) entered into an Amendment to Common Stock Purchase Warrant (the “Amendment”) with s certain institutional investor to amend that certain Common Stock Purchase Warrant dated March 27, 2023 issued by the Company to such investor (the “Original Warrant”) to reduce the exercise price under Section 2(b) thereunder to $2.85 per share.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-046392","anchor_url":"https://secwatch.observer/filing/0001493152-23-046392#claim-6f26fdb2be7d5f8f5207b7bada5d84406218c7b7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223046392/0001493152-23-046392-index.htm"},{"fact_type":"governance_change","fact_key":"22461740f8c35d29c5bb7a9366cbd17a5fe796b3","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-12-13T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2023-12-12","item_codes_triggered":["5.03"],"summary_text":"Lowered quorum requirement for shareholder meetings from majority to one-third of outstanding shares"},"claim":"INVO Fertility, Inc.: Lowered quorum requirement for shareholder meetings from majority to one-third of outstanding shares (effective 2023-12-12).","evidence_excerpt":"The Amendment amends and restates in its entirety Article III, Section 8 of the Bylaws to lower the quorum requirement for shareholder meetings from requiring the holders of a majority of the Company’s shares of stock issued and outstanding and entitled to vote thereat to be present in person or represented by proxy to one-third of the holders of the Company’s stock issued and outstanding and entitled to vote thereat to be present in person or represented by proxy.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-044734","anchor_url":"https://secwatch.observer/filing/0001493152-23-044734#claim-22461740f8c35d29c5bb7a9366cbd17a5fe796b3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223044734/0001493152-23-044734-index.htm"},{"fact_type":"governance_change","fact_key":"72a9925b89679e9e3227ad30d59cff934c36561c","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-11-20T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-11-20","item_codes_triggered":["5.03"],"summary_text":"The Company filed a Certificate of Designation for Series B Convertible Preferred Stock, establishing its rights, preferences, and privileges."},"claim":"INVO Fertility, Inc.: The Company filed a Certificate of Designation for Series B Convertible Preferred Stock, establishing its rights, preferences, and privileges (effective 2023-11-20).","evidence_excerpt":"On November 20, 2023, the Company filed with the Nevada Secretary of State a Certificate of Designation of Series B Convertible Preferred Stock (the “ Series B Certificate of Designation ”) which sets forth the rights, preferences, and privileges of the Series B Preferred Stock (the “ Series B Preferred ”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-042144","anchor_url":"https://secwatch.observer/filing/0001493152-23-042144#claim-72a9925b89679e9e3227ad30d59cff934c36561c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223042144/0001493152-23-042144-index.htm"},{"fact_type":"governance_change","fact_key":"de80a2ece8f15bf5fd46096ab1a881bf4d3ebd6c","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-11-20T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-11-20","item_codes_triggered":["5.03"],"summary_text":"The Company filed Certificates of Designation for two new series of preferred stock: Series A Convertible Preferred Stock and Series B Convertible Preferred Stock, setting forth the rights, preferences, and privileges of each series."},"claim":"INVO Fertility, Inc.: The Company filed Certificates of Designation for two new series of preferred stock: Series A Convertible Preferred Stock and Series B Convertible Preferred Stock, setting forth the rights, preferences, and privileges of each series (effective 2023-11-20).","evidence_excerpt":"On November 20, 2023, the Company filed with the Nevada Secretary of State a Certificate of Designation of Series A Convertible Preferred Stock (the “ Series A Certificate of Designation ”) which sets forth the rights, preferences, and privileges of the Series A Preferred Stock (the “ Series A Preferred ”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-042144","anchor_url":"https://secwatch.observer/filing/0001493152-23-042144#claim-de80a2ece8f15bf5fd46096ab1a881bf4d3ebd6c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223042144/0001493152-23-042144-index.htm"},{"fact_type":"material_agreement","fact_key":"f167341e1b2a0285e7179b5ae6d35cacc9f9b91e","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-11-20T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Share Exchange Agreement","agreement_type":"equity_purchase","counterparty":"Cytovia Therapeutics Holdings, Inc.","effective_date":"2023-11-19","item_codes_triggered":["1.01"],"value_text":null},"claim":"INVO Fertility, Inc. entered into Share Exchange Agreement with Cytovia Therapeutics Holdings, Inc. (effective 2023-11-19).","evidence_excerpt":"On November 19, 2023, the Company entered into a share exchange agreement (the “ Share Exchange Agreement ”) with Cytovia Therapeutics Holdings, Inc., a Delaware corporation (“ Cytovia ”) for Cytovia’s acquisition of 1,200,000 shares of the Company’s newly designated Series B Preferred Stock in exchange for 163,637 shares of common stock of NAYA held by Cytovia valued at $6,000,000","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-042144","anchor_url":"https://secwatch.observer/filing/0001493152-23-042144#claim-f167341e1b2a0285e7179b5ae6d35cacc9f9b91e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223042144/0001493152-23-042144-index.htm"},{"fact_type":"earnings_release","fact_key":"9f16e1ccab2198e57d0868b603c3359bf0568642","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-11-13T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the three months ended September 30, 2023","report_date":"2023-11-13","result_type":"reported_results","revenue_text":null},"claim":"INVO Fertility, Inc. reported financial results for the three months ended September 30, 2023.","evidence_excerpt":"On November 13, 2023, INVO Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the period ended September 30, 2023. The text of the press release is furnished as Exhibit 99.1 to this current report.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-040500","anchor_url":"https://secwatch.observer/filing/0001493152-23-040500#claim-9f16e1ccab2198e57d0868b603c3359bf0568642","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223040500/0001493152-23-040500-index.htm"},{"fact_type":"material_agreement","fact_key":"770b94c95f94b1e20df39cfde70f0e4119af8498","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-10-26T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Agreement and Plan of Merger","agreement_type":"merger","counterparty":"NAYA Biosciences, Inc.","effective_date":"2023-10-22","item_codes_triggered":["1.01"],"value_text":null},"claim":"INVO Fertility, Inc. entered into Agreement and Plan of Merger with NAYA Biosciences, Inc. (effective 2023-10-22).","evidence_excerpt":"On October 22, 2023, INVO Bioscience, Inc., a Nevada corporation (the “ Company ”), INVO Merger Sub Inc., a wholly owned subsidiary of the Company and a Delaware corporation (“ Merger Sub ”), and NAYA Biosciences, Inc., a Delaware corporation (“ NAYA ”), entered into an Agreement and Plan of Merger, as amended on October 25, 2023 (collectively, the “ Merger Agreement ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-038408","anchor_url":"https://secwatch.observer/filing/0001493152-23-038408#claim-770b94c95f94b1e20df39cfde70f0e4119af8498","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223038408/0001493152-23-038408-index.htm"},{"fact_type":"governance_change","fact_key":"7806f4c8eceb6da3efd67095b1790dbc981c1220","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-10-16T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-10-13","item_codes_triggered":["5.03"],"summary_text":"Increased authorized shares of common stock from 6,250,000 to 50,000,000."},"claim":"INVO Fertility, Inc.: Increased authorized shares of common stock from 6,250,000 to 50,000,000 (effective 2023-10-13).","evidence_excerpt":"On October 13, 2023, the Company filed a Certificate of Amendment (the “Amendment”) to its Articles of Incorporation to increase its authorized shares of common stock from 6,250,000 shares to 50,000,000 shares.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-037278","anchor_url":"https://secwatch.observer/filing/0001493152-23-037278#claim-7806f4c8eceb6da3efd67095b1790dbc981c1220","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223037278/0001493152-23-037278-index.htm"},{"fact_type":"shareholder_vote","fact_key":"3ed2646b3c6a874a75a8ef3a88b8d4b3e94457ac","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-10-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-10-13","outcome":"failed","proposal_text":"Reduce the exercise price of the March 2023 private placement warrants from $12.60 per share to $2.85 per share (for purposes of Nasdaq Marketplace Rule 5635(d))","proposal_type":"other","results":[{"broker_non_votes":"601,894","subject":null,"votes_abstain":"8,318","votes_against":"484,695","votes_for":"462,694","votes_withheld":"0"}]},"claim":"INVO Fertility, Inc. shareholders rejected Reduce the exercise price of the March 2023 private placement warrants from $12.60 per share to $2.85 per share (for purposes of Nasdaq Marketplace Rule 5635(d)) at the 2023-10-13 meeting.","evidence_excerpt":"Proposal 2: At the Special Meeting, the shareholders failed to approve, for the purposes of Nasdaq Marketplace Rule 5635(d), the reduction of the exercise price for the March 2023 private placement warrants from $12.60 per share to $2.85 per share (the “Warrant Exercise Price Reduction”). The result of the votes that failed to approve the Warrant Exercise Price Reduction was as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 462,694 484,695 8,318 601,894","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-037278","anchor_url":"https://secwatch.observer/filing/0001493152-23-037278#claim-3ed2646b3c6a874a75a8ef3a88b8d4b3e94457ac","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223037278/0001493152-23-037278-index.htm"},{"fact_type":"shareholder_vote","fact_key":"06986dde8467301ef8a70cabaca69f474ef7ebc5","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-10-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-10-13","outcome":"passed","proposal_text":"Increase the number of authorized shares of common stock from 6,250,000 to 50,000,000","proposal_type":"other","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"6,276","votes_against":"186,556","votes_for":"1,364,769","votes_withheld":"0"}]},"claim":"INVO Fertility, Inc. shareholders approved Increase the number of authorized shares of common stock from 6,250,000 to 50,000,000 at the 2023-10-13 meeting.","evidence_excerpt":"On October 13, 2023, the Company held a special meeting of shareholders (the “ Special Meeting ”) for the purpose of holding a shareholder vote on Proposals 1 and 2 set forth below. The total number of shares entitled to vote at the Special Meeting was 2,467,256 and there were present at the Meeting, in person or by proxy, 1,557,601 shares, which constituted a quorum for the Special Meeting. The final results for each of the matters submitted to a vote of shareholders at the Special Meeting, as set forth in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on September 1, 2023, as amended, are as follows: Proposal 1. At the Special Meeting, the shareholders approved an increase to the number of authorized shares of the Company’s common stock from 6,250,000 shares to 50,000,000 shares (the “Authorized Share Increase”). The result of the votes to approve the Authorized Share Increase was as follows : For against abstain Broker Non-Votes 1,364,769","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-037278","anchor_url":"https://secwatch.observer/filing/0001493152-23-037278#claim-06986dde8467301ef8a70cabaca69f474ef7ebc5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223037278/0001493152-23-037278-index.htm"},{"fact_type":"debt_financing","fact_key":"91d1d31e0efd94063c31857cf5829613898a9769","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-10-05T23:59:59+00:00","payload":{"counterparty":"Decathlon Alpha V LP","effective_date":"2023-09-29","event":"incurrence","instrument_type":"loan","interest_rate_text":"based on a minimum amount that increases from thirty five percent (35%) of the L","item_codes_triggered":["2.03"],"maturity_text":"June 29, 2028","principal_text":"$1,500,000"},"claim":"INVO Fertility, Inc. incurred loan of $1,500,000 with Decathlon Alpha V LP at based on a minimum amount that increases from thirty five percent (35%) of the L maturing June 29, 2028.","evidence_excerpt":"under which the Lender made a revenue loan advance in the gross amount of $1,500,000","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-036364","anchor_url":"https://secwatch.observer/filing/0001493152-23-036364#claim-91d1d31e0efd94063c31857cf5829613898a9769","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223036364/0001493152-23-036364-index.htm"},{"fact_type":"material_agreement","fact_key":"2613273da1f290e9868bff2abe21408ab4a3c57a","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-10-05T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Revenue Loan and Security Agreement","agreement_type":"credit_facility","counterparty":"Decathlon Alpha V LP","effective_date":"2023-09-29","item_codes_triggered":["1.01"],"value_text":"$1,500,000"},"claim":"INVO Fertility, Inc. entered into Revenue Loan and Security Agreement with Decathlon Alpha V LP valued at $1,500,000 (effective 2023-09-29).","evidence_excerpt":"On September 29, 2023, INVO Bioscience, Inc. (the “Company”), Steven Shum, as a Key Person, and the Company’s wholly-owned subsidiaries Bio X Cell, Inc, INVO Centers, LLC, Wood Violet Fertility LLC, Fertility Labs of Wisconsin LLC and Orange Blossom Fertility LLC as guarantors (the “Guarantors”), entered into a Revenue Loan and Security Agreement (the “Loan Agreement”) with Decathlon Alpha V LP (the “Lender”) under which the Lender made a revenue loan advance in the gross amount of $1,500,000 (the “Loan”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-036364","anchor_url":"https://secwatch.observer/filing/0001493152-23-036364#claim-2613273da1f290e9868bff2abe21408ab4a3c57a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223036364/0001493152-23-036364-index.htm"},{"fact_type":"debt_financing","fact_key":"70c3e2b0f2501d5621196df410e6147f972d6272","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-09-01T23:59:59+00:00","payload":{"counterparty":"a merchant","effective_date":"2023-08-31","event":"incurrence","instrument_type":"other","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":null,"principal_text":"$746,750"},"claim":"INVO Fertility, Inc. incurred debt of $746,750 with a merchant.","evidence_excerpt":"On August 31, 2023, INVO Bioscience, Inc. (the “Company”) entered into a Standard Merchant Cash Advance Agreement (the “Cash Advance Agreement”) with a merchant (the “Merchant”) under which the Merchant purchased $746,750 of our receivables for a gross purchase price of $515,000.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-031521","anchor_url":"https://secwatch.observer/filing/0001493152-23-031521#claim-70c3e2b0f2501d5621196df410e6147f972d6272","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223031521/0001493152-23-031521-index.htm"},{"fact_type":"material_agreement","fact_key":"adb4ad3d27036c85e90584d505271cdc7d9e238c","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-09-01T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Standard Merchant Cash Advance Agreement","agreement_type":"other","counterparty":"a merchant (the \"Merchant\")","effective_date":"2023-08-31","item_codes_triggered":["1.01"],"value_text":"$746,750 of our receivables for a gross purchase price of $515,000"},"claim":"INVO Fertility, Inc. entered into Standard Merchant Cash Advance Agreement with a merchant (the \"Merchant\") valued at $746,750 of our receivables for a gross purchase price of $515,000 (effective 2023-08-31).","evidence_excerpt":"On August 31, 2023, INVO Bioscience, Inc. (the \"Company\") entered into a Standard Merchant Cash Advance Agreement (the \"Cash Advance Agreement\") with a merchant (the \"Merchant\") under which the Merchant purchased $746,750 of our receivables for a gross purchase price of $515,000.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-031521","anchor_url":"https://secwatch.observer/filing/0001493152-23-031521#claim-adb4ad3d27036c85e90584d505271cdc7d9e238c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223031521/0001493152-23-031521-index.htm"},{"fact_type":"earnings_release","fact_key":"04d6a9159c19540a15fc044c0f8f9d1be99b11cb","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-08-14T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the second quarter ended June 30, 2023","report_date":"2023-08-14","result_type":"reported_results","revenue_text":"$315,902"},"claim":"INVO Fertility, Inc. reported the second quarter ended June 30, 2023 results: revenue $315,902.","evidence_excerpt":"for the second quarter ended\nJune 30, 2023 and provided a business update. Q2\n2023 Financial Highlights (all metrics compared to Q2 2022 unless otherwise noted) ● Revenue\n was $315,902, an increase of 116% compared to $146,135. ● Clinic\n revenue increased 126% to $254,364, compared to $112,358. All reported clinic revenue is derived from the Company’s INVO","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-028451","anchor_url":"https://secwatch.observer/filing/0001493152-23-028451#claim-04d6a9159c19540a15fc044c0f8f9d1be99b11cb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223028451/0001493152-23-028451-index.htm"},{"fact_type":"ma_transaction","fact_key":"3e3c80f0e007715566cc9c2220a521a5c309d741","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-08-11T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2023-08-10","consideration_text":"$10 million","counterparty":"Wisconsin Fertility Institute (the Clinic, comprised of Wisconsin Fertility and Reproductive Surgery Associates, S.C. and Fertility Labs of Wisconsin, LLC)","effective_date":"2023-08-10","item_codes_triggered":["2.01"]},"claim":"INVO Fertility, Inc. completed an acquisition involving Wisconsin Fertility Institute (the Clinic, comprised of Wisconsin Fertility and Reproductive Surgery Associates, S.C. and Fertility Labs of Wisconsin, LLC) for $10 million (closed 2023-08-10).","evidence_excerpt":"On August 10, 2023, INVO through Buyer consummated its acquisition of the Wisconsin Fertility Institute (the \"Clinic\") for a combined purchase price of $10 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-027782","anchor_url":"https://secwatch.observer/filing/0001493152-23-027782#claim-3e3c80f0e007715566cc9c2220a521a5c309d741","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223027782/0001493152-23-027782-index.htm"},{"fact_type":"material_agreement","fact_key":"dcdc39f400a262f17a981af908385c69535f212d","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-08-08T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Warrant Agent Agreement","agreement_type":"other","counterparty":"Transfer Online, Inc.","effective_date":"2023-08-08","item_codes_triggered":["1.01"],"value_text":null},"claim":"INVO Fertility, Inc. entered into Warrant Agent Agreement with Transfer Online, Inc. (effective 2023-08-08).","evidence_excerpt":"On August 8, 2023, the Company entered into a warrant agency agreement (the “Warrant Agent Agreement”), with Transfer Online, Inc. appointing Transfer Online, Inc. as Warrant Agent for the Warrants.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-027193","anchor_url":"https://secwatch.observer/filing/0001493152-23-027193#claim-dcdc39f400a262f17a981af908385c69535f212d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223027193/0001493152-23-027193-index.htm"},{"fact_type":"material_agreement","fact_key":"00118b71f4d1fa534f9df3bb6c135015bb9671ed","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-08-08T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Placement Agency Agreement","agreement_type":"underwriting","counterparty":"Maxim Group LLC","effective_date":"2023-08-04","item_codes_triggered":["1.01"],"value_text":null},"claim":"INVO Fertility, Inc. entered into Placement Agency Agreement with Maxim Group LLC (effective 2023-08-04).","evidence_excerpt":"Also in connection with the Offering, on August 4, 2023, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC (the “Placement Agent”), pursuant to which (i) the Placement Agent agreed to act as placement agent on a “best efforts” basis in connection with the Offering and (ii) the Company agreed to pay the Placement Agent an aggregate fee equal to 7.0% of the gross proceeds raised in the offering (or 5.0% in the case of certain investors) and warrants to purchase up to 110,600 shares of Common Stock at an exercise price of $3.14 per share (the “Placement Agent Warrants”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-027193","anchor_url":"https://secwatch.observer/filing/0001493152-23-027193#claim-00118b71f4d1fa534f9df3bb6c135015bb9671ed","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223027193/0001493152-23-027193-index.htm"},{"fact_type":"material_agreement","fact_key":"74fdab90e2f3a1eb4ee0923c21ff120db3eabc13","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-08-08T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"equity_purchase","counterparty":"certain institutional and other investors","effective_date":"2023-08-04","item_codes_triggered":["1.01"],"value_text":"approximately $4.5 million"},"claim":"INVO Fertility, Inc. entered into Purchase Agreement with certain institutional and other investors valued at approximately $4.5 million (effective 2023-08-04).","evidence_excerpt":"On August 4, 2023, INVO Bioscience, Inc., a Nevada corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional and other investors, pursuant to which the Company agreed to issue and sell to such investors in a public offering (the “Offering”), 1,580,000 units (the “Units”) at a price of $2.85 per Unit, with each Unit consisting of (i) one share) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company, and (ii) two common stock purchase warrants (the “Warrants”), each exercisable for one share of Common Stock.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-027193","anchor_url":"https://secwatch.observer/filing/0001493152-23-027193#claim-74fdab90e2f3a1eb4ee0923c21ff120db3eabc13","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223027193/0001493152-23-027193-index.htm"},{"fact_type":"material_agreement","fact_key":"579f4e679c258e9e87a898282653c52653647c70","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-08-02T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Membership Interest Purchase Agreement","agreement_type":"asset_purchase","counterparty":"Fertility Labs of Wisconsin, LLC","effective_date":"2023-07-31","item_codes_triggered":["1.01"],"value_text":"Extended closing date to August 10, 2023; sellers retain pre-closing accounts receivable"},"claim":"INVO Fertility, Inc. amended Membership Interest Purchase Agreement with Fertility Labs of Wisconsin, LLC valued at Extended closing date to August 10, 2023; sellers retain pre-closing accounts receivable (effective 2023-07-31).","evidence_excerpt":"On July 7, 2023, Buyer entered into a closing agreement (the “MIPA Closing Agreement”) with Fertility Labs of Wisconsin, LLC, a Wisconsin limited liability company (“FLOW”), IVF Science, LLC and Dr. Pritts as trustee for the Elizabeth Pritts Revocable Living Trust (each a “FLOW Seller” and collectively the “FLOW Sellers”) and the Sellers’ Representative (as defined in that certain Membership Interest Purchase Agreement dated March 16, 2023 between the parties listed above (the “Membership Interest Purchase Agreement”)","confidence":0.94,"filing_url":"https://secwatch.observer/filing/0001493152-23-026331","anchor_url":"https://secwatch.observer/filing/0001493152-23-026331#claim-579f4e679c258e9e87a898282653c52653647c70","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223026331/0001493152-23-026331-index.htm"},{"fact_type":"material_agreement","fact_key":"75470a01a4a04c425a2347b9738b75575e06ff7a","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-08-02T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Asset Purchase Agreement","agreement_type":"asset_purchase","counterparty":"Wisconsin Fertility and Reproductive Surgery Associates, S.C.","effective_date":"2023-07-31","item_codes_triggered":["1.01"],"value_text":"Extended closing date to August 10, 2023; company assumed inter-company loan of $268,054.32; sellers"},"claim":"INVO Fertility, Inc. amended Asset Purchase Agreement with Wisconsin Fertility and Reproductive Surgery Associates, S.C. valued at Extended closing date to August 10, 2023; company assumed inter-company loan of $268,054.32; sellers (effective 2023-07-31).","evidence_excerpt":"On July 7, 2023 Wood Violet Fertility LLC (“Buyer”), a wholly owned subsidiary of INVO Bioscience, Inc. (the “Company”) entered into a closing agreement (the “APA Closing Agreement”) with Wisconsin Fertility and Reproductive Surgery Associates, S.C., a Wisconsin professional service corporation d/b/a Wisconsin Fertility Institute (“WFRSA”), The Elizabeth Pritts Revocable Living Trust (“Seller”) and Dr. Elizabeth Pritts, an individual and sole trust of Seller (“Dr. Pritts”, and together with the Seller, the “Seller Parties” related to that certain Asset Purchase Agreement dated March 16, 2023 between the parties listed above – the “Asset Purchase Agreement”)","confidence":0.94,"filing_url":"https://secwatch.observer/filing/0001493152-23-026331","anchor_url":"https://secwatch.observer/filing/0001493152-23-026331#claim-75470a01a4a04c425a2347b9738b75575e06ff7a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223026331/0001493152-23-026331-index.htm"},{"fact_type":"governance_change","fact_key":"bb69d31943442b17c4d19d5e8db943337b7bf7e7","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-07-27T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-07-28","item_codes_triggered":["5.03"],"summary_text":"Effected a 1-for-20 reverse stock split of common stock, adjusting authorized shares to 6,250,000."},"claim":"INVO Fertility, Inc.: Effected a 1-for-20 reverse stock split of common stock, adjusting authorized shares to 6,250,000 (effective 2023-07-28).","evidence_excerpt":"On July 26, 2023, INVO Bioscience, Inc. (the “Company”) filed a Certificate of Change (the “Certificate of Change”) with the Secretary of State of the State of Nevada to effectuate a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding and authorized shares of common stock, par value $0.0001 per share (“Common Stock”). The Reverse Stock Split will become effective at 12:01 a.m., Eastern Time, on Friday, July 28, 2023","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-025720","anchor_url":"https://secwatch.observer/filing/0001493152-23-025720#claim-bb69d31943442b17c4d19d5e8db943337b7bf7e7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223025720/0001493152-23-025720-index.htm"},{"fact_type":"debt_financing","fact_key":"02f00b9f9a17c47b040d179bfd8fc071a7b186d1","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-07-21T23:59:59+00:00","payload":{"counterparty":"Cedar Advance LLC","effective_date":"2023-07-20","event":"incurrence","instrument_type":"other","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":null,"principal_text":"$543,750"},"claim":"INVO Fertility, Inc. incurred debt of $543,750 with Cedar Advance LLC.","evidence_excerpt":"On July 20, 2023, INVO Bioscience, Inc. (the “Company”) entered into a Standard Merchant Cash Advance Agreement (the “Cash Advance Agreement”) with Cedar Advance LLC (“Cedar”) under which Cedar purchased $543,750 of our receivables for a gross purchase price of $375,000.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-025289","anchor_url":"https://secwatch.observer/filing/0001493152-23-025289#claim-02f00b9f9a17c47b040d179bfd8fc071a7b186d1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223025289/0001493152-23-025289-index.htm"},{"fact_type":"material_agreement","fact_key":"8046062d58fdfd93c962ceb6a04ca1150fc548f2","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-07-21T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amended Letter Agreement","agreement_type":"other","counterparty":"JAG Multi Investments LLC","effective_date":"2023-07-21","item_codes_triggered":["1.01"],"value_text":"Amendment removes references to warrant issuance and repricing; rescinds July 10, 2023 warrant to pu"},"claim":"INVO Fertility, Inc. amended Amended Letter Agreement with JAG Multi Investments LLC valued at Amendment removes references to warrant issuance and repricing; rescinds July 10, 2023 warrant to pu (effective 2023-07-21).","evidence_excerpt":"JAG Amended Letter Agreement On July 21, 2023 the Company entered into an amended and restated letter agreement (the “Amended Letter Agreement”) with JAG Multi Investments LLC (“JAG”) to restate the terms of that certain July 10, 2023 letter agreement between the Company and JAG (the “Original Letter Agreement”). The Amended Letter Agreement removes all references to issuance of a new warrant and repricing of warrants referenced in the Original Letter Agreement, both of which are void ab initio. Since the parties agreed that the warrant issuance to JAG referred to in the Original Letter Agreement is void ab initio, the July 10, 2023 warrant to purchase 150,000 shares of common stock of the Company to JAG is rescinded and cancelled and of no force and effect.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-025289","anchor_url":"https://secwatch.observer/filing/0001493152-23-025289#claim-8046062d58fdfd93c962ceb6a04ca1150fc548f2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223025289/0001493152-23-025289-index.htm"},{"fact_type":"material_agreement","fact_key":"9f4c44365d4adbd0d244bfcb8a3297b2004f4039","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-07-21T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Standard Merchant Cash Advance Agreement","agreement_type":"credit_facility","counterparty":"Cedar Advance LLC","effective_date":"2023-07-20","item_codes_triggered":["1.01"],"value_text":"Cedar purchased $543,750 of receivables for gross purchase price of $375,000, net proceeds $356,250,"},"claim":"INVO Fertility, Inc. entered into Standard Merchant Cash Advance Agreement with Cedar Advance LLC valued at Cedar purchased $543,750 of receivables for gross purchase price of $375,000, net proceeds $356,250, (effective 2023-07-20).","evidence_excerpt":"July 2023 Standard Merchant Cash Advance Agreement On July 20, 2023, INVO Bioscience, Inc. (the “Company”) entered into a Standard Merchant Cash Advance Agreement (the “Cash Advance Agreement”) with Cedar Advance LLC (“Cedar”) under which Cedar purchased $543,750 of our receivables for a gross purchase price of $375,000. We received net proceeds of $356,250. Until the purchase price has been repaid, we agreed to pay Cedar $19,419.64 per week. If we repay the purchase price within 30-days then the amount payable shall be reduced to $465,000. In addition, we granted Cedar a security interest in our accounts, including deposit accounts and accounts receivable. We intend to use the proceeds for working capital and general corporate purposes.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-025289","anchor_url":"https://secwatch.observer/filing/0001493152-23-025289#claim-9f4c44365d4adbd0d244bfcb8a3297b2004f4039","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223025289/0001493152-23-025289-index.htm"},{"fact_type":"debt_financing","fact_key":"c90a5894cfa4f5d1009cb681380f133dc9ffb528","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-07-13T23:59:59+00:00","payload":{"counterparty":"JAG Multi Investments LLC","effective_date":"2023-07-10","event":"amendment","instrument_type":"loan","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"extended to September 30, 2023","principal_text":"$500,000"},"claim":"INVO Fertility, Inc. amended loan of $500,000 with JAG Multi Investments LLC maturing extended to September 30, 2023.","evidence_excerpt":"the date on which JAG can demand payment of principal, fees and any interest under those certain demand promissory previously issued to JAG by the Company for a total of $500,000, of which JAG may demand payment of $500,000 as of the date hereof, be extended to September 30, 2023","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-024463","anchor_url":"https://secwatch.observer/filing/0001493152-23-024463#claim-c90a5894cfa4f5d1009cb681380f133dc9ffb528","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223024463/0001493152-23-024463-index.htm"},{"fact_type":"debt_financing","fact_key":"c3c52a079918641675797b6cd8c7e6a9416e4baf","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-07-13T23:59:59+00:00","payload":{"counterparty":"JAG Multi Investments LLC","effective_date":"2023-07-10","event":"incurrence","instrument_type":"loan","interest_rate_text":"interest free until August 31, 2023, then 10% annual interest","item_codes_triggered":["2.03"],"maturity_text":"demand promissory note","principal_text":"$100,000"},"claim":"INVO Fertility, Inc. incurred loan of $100,000 with JAG Multi Investments LLC at interest free until August 31, 2023, then 10% annual interest maturing demand promissory note.","evidence_excerpt":"uly 10, 2023, the Company entered into a letter agreement (the “Agreement”) with JAG Multi Investments LLC (“JAG”),\na related party to Andrea Goren, our CFO, who is a beneficiary of JAG but does not have any control over JAG’s investment decisions","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-024463","anchor_url":"https://secwatch.observer/filing/0001493152-23-024463#claim-c3c52a079918641675797b6cd8c7e6a9416e4baf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223024463/0001493152-23-024463-index.htm"},{"fact_type":"material_agreement","fact_key":"0d694817ce2489c186287dbebdf0dd6b98d1ec3c","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-07-13T23:59:59+00:00","payload":{"action":"entry","agreement_name":"MIPA Closing Agreement","agreement_type":"equity_purchase","counterparty":"FLOW Sellers","effective_date":"2023-07-07","item_codes_triggered":["1.01"],"value_text":"$40,000"},"claim":"INVO Fertility, Inc. entered into MIPA Closing Agreement with FLOW Sellers valued at $40,000 (effective 2023-07-07).","evidence_excerpt":"On July 7, 2023, Buyer entered into a closing agreement (the “MIPA Closing Agreement”) with Fertility Labs of Wisconsin, LLC, a Wisconsin limited liability company (“FLOW”), IVF Science, LLC and Dr. Pritts as trustee for the Elizabeth Pritts Revocable Living Trust (each a “FLOW Seller” and collectively the “FLOW Sellers”) and the Sellers’ Representative (as defined in that certain Membership Interest Purchase Agreement dated March 16, 2023 between the parties listed above (the “MIPA”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-024463","anchor_url":"https://secwatch.observer/filing/0001493152-23-024463#claim-0d694817ce2489c186287dbebdf0dd6b98d1ec3c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223024463/0001493152-23-024463-index.htm"},{"fact_type":"material_agreement","fact_key":"cf39f0f676e7f6403d030d0a6f6327c3c24c011c","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-07-13T23:59:59+00:00","payload":{"action":"entry","agreement_name":"APA Closing Agreement","agreement_type":"asset_purchase","counterparty":"Wisconsin Fertility and Reproductive Surgery Associates, S.C., The Elizabeth Pritts Revocable Living Trust, and Dr. Elizabeth Pritts","effective_date":"2023-07-07","item_codes_triggered":["1.01"],"value_text":"$10,000"},"claim":"INVO Fertility, Inc. entered into APA Closing Agreement with Wisconsin Fertility and Reproductive Surgery Associates, S.C., The Elizabeth Pritts Revocable Living Trust, and Dr. Elizabeth Pritts valued at $10,000 (effective 2023-07-07).","evidence_excerpt":"On July 7, 2023, Wood Violet Fertility LLC (“Buyer”), a wholly owned subsidiary of INVO Bioscience, Inc. (the “Company”) entered into a closing agreement (the “APA Closing Agreement”) with Wisconsin Fertility and Reproductive Surgery Associates, S.C., a Wisconsin professional service corporation d/b/a Wisconsin Fertility Institute (“WFRSA”), The Elizabeth Pritts Revocable Living Trust (“Seller”) and Dr. Elizabeth Pritts, an individual and sole trust of Seller (“Dr. Pritts”, and together with the Seller, the “Seller Parties” related to that certain Asset Purchase Agreement dated March 16, 2023 between the parties listed above – the “APA”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-024463","anchor_url":"https://secwatch.observer/filing/0001493152-23-024463#claim-cf39f0f676e7f6403d030d0a6f6327c3c24c011c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223024463/0001493152-23-024463-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"3c3cdccfdfc0f61b4f3e0a5e5925e19b01780b28","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-07-13T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"plan_due","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2023-07-11","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"INVO Fertility, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"July 11, 2023, the Company received a notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market\nLLC (“Nasdaq”) that, based upon the Company’s non-compliance with the minimum bid price requirement set forth in Nasdaq\nListing Rule 5550(a)(2) (the “Rule”), as of July 10, 2023, the Nasdaq Hearing Panel (the “Panel”) will consider\nsuch non-compliance in its decision regarding the Company’s continued listing on Nasdaq. The\nCompany plans to timely submit to the Panel confirmation of its plan to regain compliance under the Rule, providing similar information\nto that present","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-024463","anchor_url":"https://secwatch.observer/filing/0001493152-23-024463#claim-3c3cdccfdfc0f61b4f3e0a5e5925e19b01780b28","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223024463/0001493152-23-024463-index.htm"},{"fact_type":"material_agreement","fact_key":"50e7fcdb05a0f7f4fb69afa4bffb956253bc1ceb","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-07-07T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Payoff Agreement","agreement_type":"other","counterparty":"Armistice Capital Markets Ltd.","effective_date":"2023-07-07","item_codes_triggered":["1.01"],"value_text":null},"claim":"INVO Fertility, Inc. entered into Payoff Agreement with Armistice Capital Markets Ltd. (effective 2023-07-07).","evidence_excerpt":"In connection with the Armistice Amendment, the Company also entered into a Payoff Commitment Agreement and Confession of Judgment (the “Payoff Agreement”) with Armistice on July 7, 2023 which provides that if INVO fails to pay the Armistice Amendment Fee when due, the Company confesses judgment in favor of Armistice.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-023990","anchor_url":"https://secwatch.observer/filing/0001493152-23-023990#claim-50e7fcdb05a0f7f4fb69afa4bffb956253bc1ceb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223023990/0001493152-23-023990-index.htm"},{"fact_type":"material_agreement","fact_key":"4f4ee9a805f3edf57b7a0c81c1818991183c9b64","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-07-07T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Armistice Amendment","agreement_type":"equity_purchase","counterparty":"Armistice Capital Markets Ltd.","effective_date":"2023-07-07","item_codes_triggered":["1.01"],"value_text":null},"claim":"INVO Fertility, Inc. amended Armistice Amendment with Armistice Capital Markets Ltd. (effective 2023-07-07).","evidence_excerpt":"On July 7, 2023, INVO Bioscience, Inc., a Nevada corporation (the “Company”), entered into an Amendment to Securities Purchase Agreement (the “Armistice Amendment”) with Armistice Capital Markets Ltd. to delete Section 4.12(a) of our March 23, 2023 Securities Purchase Agreement (the “Armistice SPA”) with Armistice pursuant to which we agreed that from March 23, 2023 until 45 days after the effective date of the Resale Registration Statement (as defined) we would not (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto, other than the prospectus supplement filed in connection with that offering and the Resale Registration Statement (the “Subsequent Equity Financing Provision”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-023990","anchor_url":"https://secwatch.observer/filing/0001493152-23-023990#claim-4f4ee9a805f3edf57b7a0c81c1818991183c9b64","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223023990/0001493152-23-023990-index.htm"},{"fact_type":"material_agreement","fact_key":"f3b20a2eeae6108cc552928a0270ad3e5dc95442","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-06-30T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Membership Interest Purchase Agreement","agreement_type":"equity_purchase","counterparty":"FLOW, IVF Science, LLC, and Dr. Elizabeth Pritts as trustee for the Elizabeth Pritts Revocable List Trust","effective_date":"2023-03-16","item_codes_triggered":["1.01"],"value_text":"$2,000,000"},"claim":"INVO Fertility, Inc. entered into Membership Interest Purchase Agreement with FLOW, IVF Science, LLC, and Dr. Elizabeth Pritts as trustee for the Elizabeth Pritts Revocable List Trust valued at $2,000,000 (effective 2023-03-16).","evidence_excerpt":"On March 16, 2023, Buyer entered into a Membership Interest Purchase Agreement (the “MIPA”) with FLOW, IVF Science, LLC, a Wisconsin limited liability company (“IVF Science”), owned by Wael Megid, Ph.D. (“Dr. Megid”), and Dr. Elizabeth Pritts as trustee for the Elizabeth Pritts Revocable List Trust, a Trust created under the laws of the State of Wisconsin (each, a “Selling Member” and collectively, the “Selling Members”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-023175","anchor_url":"https://secwatch.observer/filing/0001493152-23-023175#claim-f3b20a2eeae6108cc552928a0270ad3e5dc95442","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223023175/0001493152-23-023175-index.htm"},{"fact_type":"material_agreement","fact_key":"a8084b23fcdaa3a23a0f1546f18cad1932c1caf4","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-06-30T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Asset Purchase Agreement","agreement_type":"asset_purchase","counterparty":"WFRSA and The Elizabeth Pritts Revocable Living Trust","effective_date":"2023-03-16","item_codes_triggered":["1.01"],"value_text":null},"claim":"INVO Fertility, Inc. entered into Asset Purchase Agreement with WFRSA and The Elizabeth Pritts Revocable Living Trust (effective 2023-03-16).","evidence_excerpt":"On March 16, 2023, Buyer entered into an Asset Purchase Agreement (the “APA”) with WFRSA and The Elizabeth Pritts Revocable Living Trust (the “Seller,” together with the WFRSA, the “Seller Parties”) pursuant to which Buyer agreed to acquire the Purchased Assets (as defined in the APA) related to WFRSA’s business.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-023175","anchor_url":"https://secwatch.observer/filing/0001493152-23-023175#claim-a8084b23fcdaa3a23a0f1546f18cad1932c1caf4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223023175/0001493152-23-023175-index.htm"},{"fact_type":"material_agreement","fact_key":"cd2af70ba6294fd0625ea09ee36e82d8cba26e24","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-06-21T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Membership Interest Purchase Agreement","agreement_type":"asset_purchase","counterparty":"FLOW, IVF Science, LLC, and certain selling members","effective_date":"2023-03-16","item_codes_triggered":["1.01"],"value_text":"$2,000,000"},"claim":"INVO Fertility, Inc. entered into Membership Interest Purchase Agreement with FLOW, IVF Science, LLC, and certain selling members valued at $2,000,000 (effective 2023-03-16).","evidence_excerpt":"On March 16, 2023, Buyer entered into a Membership Interest Purchase Agreement (the “MIPA”) with FLOW, IVF Science, LLC, a Wisconsin limited liability company (“IVF Science”), owned by Wael Megid, Ph.D. (“Dr. Megid”), and Dr. Elizabeth Pritts as trustee for the Elizabeth Pritts Revocable List Trust","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-021942","anchor_url":"https://secwatch.observer/filing/0001493152-23-021942#claim-cd2af70ba6294fd0625ea09ee36e82d8cba26e24","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223021942/0001493152-23-021942-index.htm"},{"fact_type":"material_agreement","fact_key":"1d73769d48324c0b3cccbf53692fea695149300b","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-06-21T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Asset Purchase Agreement","agreement_type":"asset_purchase","counterparty":"WFRSA and The Elizabeth Pritts Revocable Living Trust","effective_date":"2023-03-16","item_codes_triggered":["1.01"],"value_text":"$500,000 less Target Closing Date Debt less the Holdback Amount of $280,000"},"claim":"INVO Fertility, Inc. entered into Asset Purchase Agreement with WFRSA and The Elizabeth Pritts Revocable Living Trust valued at $500,000 less Target Closing Date Debt less the Holdback Amount of $280,000 (effective 2023-03-16).","evidence_excerpt":"On March 16, 2023, Buyer entered into an Asset Purchase Agreement (the “APA”) with WFRSA and The Elizabeth Pritts Revocable Living Trust (the “Seller,” together with the WFRSA, the “Seller Parties”) pursuant to which Buyer agreed to acquire the Purchased Assets (as defined in the APA) related to WFRSA’s business.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-021942","anchor_url":"https://secwatch.observer/filing/0001493152-23-021942#claim-1d73769d48324c0b3cccbf53692fea695149300b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223021942/0001493152-23-021942-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"1f8a61429682146e48cc2dad81d058185a55c27d","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-05-30T23:59:59+00:00","payload":{"company_response":"Company plans to timely request a hearing before the Panel","compliance_status":"hearing_requested","cure_deadline":null,"deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"$2.5 million stockholders' equity","notice_date":"2023-05-23","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5550(b)(1)","reported_value":null,"rule_numbers":["5550(b)(1)"],"rules_cited_in_text":true},"claim":"INVO Fertility, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"May 23, 2023, INVO Bioscience, Inc. (the “Company”) was notified by the Listing Qualifications department (the “Staff”)\nof The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company’s non-compliance with the $2.5 million stockholders’\nequity requirement for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Rule”),\nas of May 22, 2023, the Company’s common stock was subject to delisting from Nasdaq unless the Company timely requests a hearing\nbefore the Nasdaq Hearings Panel (the “Panel”). The\nCompany plans to timely request a hearing be","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-019455","anchor_url":"https://secwatch.observer/filing/0001493152-23-019455#claim-1f8a61429682146e48cc2dad81d058185a55c27d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223019455/0001493152-23-019455-index.htm"},{"fact_type":"earnings_release","fact_key":"ccdd9b2d7f9f84b7bc5a7b2364ef66984f4fc895","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-05-15T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"three months ended March 31, 2023","report_date":"2023-05-15","result_type":"reported_results","revenue_text":"$348,025"},"claim":"INVO Fertility, Inc. reported three months ended March 31, 2023 results: revenue $348,025.","evidence_excerpt":"Revenue for the three months ended March 31, 2023, was $348,025 compared to $162,598 for the three months ended March 31, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-017342","anchor_url":"https://secwatch.observer/filing/0001493152-23-017342#claim-ccdd9b2d7f9f84b7bc5a7b2364ef66984f4fc895","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223017342/0001493152-23-017342-index.htm"},{"fact_type":"earnings_release","fact_key":"fee771434abc7e5e73708701e5d316717e6260cd","cik":1417926,"ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2023-04-17T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"year ended December 31, 2022","report_date":"2023-04-17","result_type":"reported_results","revenue_text":"$822,196"},"claim":"INVO Fertility, Inc. reported year ended December 31, 2022 results: revenue $822,196.","evidence_excerpt":"2022 Financial Highlights (all metrics compared to 2021 unless otherwise noted) ● Revenue increased 40% to $822,196 compared to $588,687 (excluding license revenue) in the prior year.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-012538","anchor_url":"https://secwatch.observer/filing/0001493152-23-012538#claim-fee771434abc7e5e73708701e5d316717e6260cd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223012538/0001493152-23-012538-index.htm"}]}